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Introduction 
Hypertension is an important threat to public health affecting about 26% of the world’s 
adult population, a number which is still rising.1 When left untreated, hypertension 
greatly enhances the risk of cardiovascular and renal disease. In developed countries, 
high blood pressure (11%) is the second most common potentially modifiable risk to 
loss of healthy life, only the use of tobacco (12%) ranking higher.2  
 
In the great majority of patients with hypertension, no specific cause can be found. This 
“condition” is therefore called essential or primary hypertension. The pathogenesis of 
essential hypertension is multifactorial: genetic factors play an important role as do 
factors like obesity, smoking, insulin resistance, diet (sodium, potassium and calcium 
intake) and (excessive) use of alcohol.3,4 Comprehensive evaluation will identify a 
specific cause of the hypertension in approximately five percent of the patients with high 
blood pressure. The umbrella term for all specific causes is secondary hypertension. 
Renovascular hypertension is considered to be the second most common cause of 
secondary hypertension.5 About one percent of all individuals with elevated blood 
pressure in the general population has a stenosis in one or more of their renal 
arteries.6-9 The presence of renal artery stenosis may lead to renovascular hypertension 
and renal dysfunction.10 Restoration of renal artery patency may, at least potentially, 
reverse hypertension and prevent (further) deterioration of kidney function.10 
The Maastricht angiography cohort  
Whereas the prevalence of renal artery stenosis is not so high in the general 
hypertensive population, this number rises dramatically in selected populations. For 
instance, in one study, 17% of the patients with severe or resistant hypertension that 
underwent diagnostic cardiac catheterisation had renal artery stenosis11 and the 
prevalence in patients entering dialysis programmes was estimated to be 11-14%.12 The 
relatively high occurrence of renal artery stenosis in secondary care settings contrasts 
with the rather poor understanding of the interrelationships between renal artery lumen 
reduction, renal perfusion pressure and renal blood flow on the one hand and the 
eventual consequences of this, hypertension and renal dysfunction, on the other. This 
consideration has been the major impetus for the start of studies into renal blood flow in 
the University Hospital Maastricht. As of February 1994, all patients who are referred to 
our clinic for evaluation of their hypertension are subjected to a standard diagnostic 
protocol. This includes renal angiography with selective renal blood flow measurements 
and arterial and renal venous blood sampling when patients meet one or more of the 
following criteria: hypertension despite two or more antihypertensive drugs, accelerated 
hypertension, documented atherosclerotic vascular disease in two or more vascular 
beds, presence of an abdominal bruit or an unexplained impairment of renal function in 
response to antihypertensive treatment. In many of these patients endothelial function 
has been assessed by means of infusion of vasoactive substances.13-17 The percentage 
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of patients that agree to participate is high: 98% patients who underwent selective 
baseline blood flow measurements consented to infusion of agents. Over time, the 
protocol has been adapted and extended in order to be able to elucidate other 
diagnostic and pathophysiological issues. From mid-1996 on, patients have been asked 
to donate a blood sample for genetic analysis. Since April 1999, measurements of 
intima-media thickness of the common carotid artery and aortic and brachial pulse wave 
velocity have been included in the protocol. Further, as part of the RADISH study, which 
investigated the value of computed tomographic angiography (CTA) and magnetic 
resonance angiography (MRA) for the diagnosis of renal artery stenosis, patients were 
asked to undergo CTA and MRA on the day prior to angiography between October 1998 
and October 2001.18 In addition, renal scintigraphy and/or renal ultrasound were 
commonly applied as non-invasive screenings tests. Nowadays, these latter two tests 
have been largely abandoned in our hospital because of low sensitivity for the diagnosis 
of renal artery stenosis.19 Figure 1.1. details the diagnostic protocol of patients with 
hypertension referred to our outpatient clinic and Table 1.1 shows the characteristics of 
the angiography cohort.  
 
Figure 1.1 Schematic outline of the diagnostic protocol of the Maastricht Angiography cohort. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a whether this test was performed was to the discretion of the physician; b these tests were 
performed only in patients who participated in the RADISH study. Dotted lines indicate that the 
duration of these time periods was not fixed. Usually the time between the first visit to the 
outpatient clinic and renal angiography did not exceed twelve months. 
 
Table 1.1 Patient characteristics. 
 
   
RAS- 
n=303 
FMD 
n=29 
ARAS 
n=154 
FMD and ARAS
n=4 
Total 
n=490 
Age ± SD 50 ± 13 51 ± 10 61 ± 10 44 54 ± 13 
Gender (% male) 53 27 64 50 55 
MRBF measurements
Sampling: aorta, renal veins (L+R) 
(APRC, AngII, creatinine)
Monitoring blood pressure
Renal DSA: (review of films by three radiologists)
-3 weeks:
Medication stop 
(Renal scintigraphy)a
(Renal ultrasonography) a
1st visit
IMT
PWV
ABPM
Genetics 
-1 week:
55 mmol Na+ 
-1 day
IMT
PWV
ABPM
CTAb
MRAb
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Outline of this thesis 
The studies that form the main body of this thesis investigated diagnostic, 
pathophysiological and therapeutic aspects of renal artery stenosis in the Maastricht 
angiography cohort. These studies were designed and conducted to assess whether 
these aspects could 1) discern patients with renal artery stenosis out of a group of 
patients with moderate to severe hypertension in a secondary/tertiary care population 
and/or 2) shed light on the pathophysiology of renal artery stenosis and/or renovascular 
hypertension. 
 
The gold standard for the diagnosis of renal artery stenosis still is intra-arterial digital 
subtraction angiography. However, this cannot be used routinely considering its invasive 
nature and costs. Unfortunately, none of the noninvasive screenings tests has proven to 
satisfy the requirements yet.18 Hence, patients are selected for renal angiography on the 
basis of clinical clues obtained in anamnesis and physical examination. Most textbooks 
and review articles that have proposed diagnostic strategies refer to either the clinical 
clues formulated in the 1987 report of the Working Group on Renovascular 
Hypertension or the Mann-Pickering criteria.9,20 Yet, the diagnostic accuracy of these 
clues has not been evaluated properly. Chapter 2 describes the prevalence and 
predictive value of these clues in our cohort. In addition, we tested whether a model 
incorporating clinical clues and risk factors for cardiovascular disease in general, would 
be able to select patients in whom digital subtraction angiography should be performed. 
In Chapter 3, the question has been addressed whether the prediction of the presence 
of renal artery stenosis can be further improved by knowledge about structural (intima 
media thickness of the common carotid artery) and functional (aortic pulse wave 
velocity) vessel wall properties and more accurate blood pressure measurements 
(24 hour ambulatory blood pressure measurements).  
 
It is still largely unknown if and to what extent genetic abnormalities contribute to the 
development of atherosclerotic renal artery disease. Polymorphisms in genes of the 
renin-angiotensin system and endothelial nitric oxide synthase rank high among the 
potential candidates and their association with atherosclerotic renal artery stenosis is 
reported in Chapter 4. Because association studies are especially prone to (selection) 
bias, the prevalence of the polymorphisms was also studied in an independent sample 
of patients from a general care practice. 
 
Evaluation of split renal function in patients with elevated blood pressure may be useful 
as a screening procedure to detect (unilateral) renal artery stenosis. The implicit 
assumption underlying diagnostic tests making use of this principle, is that, in the 
absence of a hemodynamically significant renal artery stenosis, blood flow through the 
kidneys will be roughly symmetrical. Whether this is truly the case has been investigated 
in Chapter 5. Chapter 6 discusses differences between kidneys supplied by (unilaterally 
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stenosed) atherosclerotic renal arteries and kidneys contralateral to these kidneys with 
respect to renal blood flow and its functional characteristics.  
 
In Chapter 7 an excursion is made to the therapy of renal artery stenosis. The goals of 
restoration of renal artery patency, are nowadays usually two-fold: to improve blood 
pressure control and to stabilize renal function. The interest in the possibe effects on 
renal function is however of relatively recent date. None of the published randomized 
clinical trials included an adequate number of patients with sufficient long duration of 
follow-up to reach a definite conclusion about the effect on renal outcome on its own. 
Chapter 7 presents a meta-analysis of all available evidence of the effect of 
revascularisation on intermediate renal outcome. 
 
A general discussion and summary of the main findings of this thesis are provided in 
Chapter 8 and 9, Chapter 10 provides a summary in Dutch. 
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Abstract 
The gold standard for the diagnosis of renal artery stenosis is digital subtraction angiography. 
However, this cannot be used routinely considering its invasive nature and costs. Presently, 
patients are selected for renal angiography on the basis of clinical clues. Yet, the diagnostic 
accuracy of these clues has not been evaluated properly. Aims of this study were: 1. to evaluate 
the ability of established clinical clues as proposed by the 1987 report of the Working Group on 
Renovascular Hypertension and the Mann-Pickering criteria to predict the presence of renal artery 
stenosis 2. to develop a model for more efficient patient selection for renal angiography. Clinical 
clues and patient characteristics were abstracted from the medical records of all patients who were 
referred to our outpatient clinic for the evaluation of hypertension and who had undergone renal 
angiography (1998-2003, n=326). Renal angiography films were examined by three radiologists. 
Most clinical clues had only limited predictive value because of a low prevalence, lack of 
discriminative ability or lack of additional information over and above other patient characteristics. 
Three clues (length difference between kidneys >10%, the presence (and extent of) extra-renal 
atherosclerosis and recent onset of hypertension), proved to be independent predictors. A model 
combing these three clues with information regarding age, pulse pressure and smoking achieved 
an optimism-corrected area under the receiver-operating characteristic curve of 0.75. Our model 
may be used as a guide to select patients for angiography and a reduction of the number of 
patients undergoing angiography may be feasible. 
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Introduction 
The prevalence of the renal artery stenosis among unselected patients with 
hypertension is low. Yet, clinicians often search thoroughly for this condition, since it is 
one of the few causes of (potentially) reversible hypertension and/or renal failure. The 
gold standard for diagnosis is digital subtraction angiography, but in view of its costs, 
invasive nature and potentially serious complications, angiography cannot be used 
routinely. Major effort has been put in the development and evaluation of non-invasive 
screening tests during the last decades. Unfortunately, however, none of these tests 
has an adequate diagnostic accuracy.1,2 Hence, we must still rely on clinical features in 
the process of selecting candidates for angiography. Most textbooks and review articles 
that have proposed diagnostic strategies refer to either the clinical clues formulated in 
the 1987 report of the Working Group on Renovascular Hypertension3 or the Mann-
Pickering criteria,4 which are primarily based on one systematic survey.5 Remarkably 
though, the diagnostic accuracy of these criteria has not been properly evaluated. 
Therefore, the present study assessed the predictive value of these clinical clues in 
patients clinically suspected of having renovascular hypertension. In addition we tested 
whether a model incorporating clinical clues and risk factors for cardiovascular disease 
in general, would be able to select patients in whom digital subtraction angiography 
should be performed. 
Materials and methods 
Patients 
The study group consisted of consecutive patients who had been referred to the 
outpatient clinic of the department of internal medicine of the University Hospital 
Maastricht for the evaluation of hypertension and who had undergone digital subtraction 
renal angiography between October 1998 and October 2003. The outpatient clinic of the 
department of internal medicine is a referral center for hypertension, but since the 
University Hospital Maastricht is the only hospital in the Maastricht region, general 
practitioners also refer patients to our clinic. Patients were eligible for this study if they 
were between 18 and 75 years of age, had a diastolic blood pressure equal to or 
exceeding 95 mmHg, and had one or more clinical characteristics suggestive of the 
presence of renovascular hypertension3,4 and/or signs commonly associated with renal 
artery disease like high serum cholesterol concentration, low serum potassium 
concentration, and/or left ventricular hypertrophy. Patients suspected of restenosis after 
treated renovascular hypertension were also included (Table 2.1). It should be noted that 
the criterion “hypertension refractory to three-drug treatment” as defined by the Working 
Group on Renovascular Hypertension was changed into “hypertension refractory to two-
drug treatment”, as was proposed by the DRASTIC investigators.6 Finally, suspicion of 
renovascular hypertension had to have been the main indication for angiography. 
Subjects with previously diagnosed yet untreated renal artery stenosis were excluded.
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Data Collection 
Data were collected using standardized forms, which included information on the above-
mentioned clinical clues as well as age, gender, body height, weight, smoking habits 
(ever-smoker versus never-smoker), duration of hypertension (in years), number of 
antihypertensive drugs used by the patient, systolic and diastolic blood pressure 
(defined as the average of the office blood pressure measurements obtained during the 
visit in which the decision was taken to perform angiography), concentrations of 
creatinine (µmol/l), cholesterol (mmol/l) and potassium (mmol/l) and results of renal 
ultrasound (length of both kidneys) and echocardiography. Diabetes mellitus was 
considered to be present when the patient used insulin or oral anti-diabetic drugs, or 
when postprandial plasma glucose levels exceeded 11.0 mmol/l. The diagnosis of 
hyperlipidemia was based on a cholesterol level above 7.0 mmol/l or the use of 
cholesterol-lowering drugs.  
Evaluation of Digital Subtraction Angiography 
Two experienced radiologists evaluated all angiographic films independently. They used 
standardized forms to report on whether or not a lesion was present as well as on the 
site, nature of the abnormality and, only in case of atherosclerotic disease, the 
percentage of (maximum) luminal reduction. If the two estimates of the degree of 
stenosis differed by 10% or more (of the highest assessment), the opinion of a third 
radiologist was decisive. A patient was considered to have renal artery stenosis if the 
angiogram showed fibromuscular dysplasia (FMD) or ≥50% luminal reduction in case of 
atherosclerotic disease, consistent with our hospitals policy to perform revascularisation 
in these cases. 
Statistical Analysis 
Predictive ability of clinical clues and derivation of the prediction model 
We explored the prevalence and predictive abilities of individual clinical clues by 
univariable regression analysis. Next, multivariable analysis was performed in order to 
calculate the contribution of each factor while accounting for all other factors in the 
model. We entered all clinical clues and risk factors into the model except for: 1 clinical 
clues that were present in less than 5% of the patients; 2 candidate predictors that 
(partially) measure the same concepts as other candidate predictors, these predictors 
were combined; and 3 candidate predictors that showed high collinearity with other 
candidate predictors. In these cases of combinations of highly correlated variables, we 
tested which variable performed best, as determined by the change in -2 Log Likelihood 
following the addition of such a variable to a model containing all other candidate 
predictors. Furthermore we introduced interaction terms into the model to test whether 
interactions between blood pressure and age and between blood pressure and smoking 
were present. We checked for any nonlinear relationship between presence of renal 
artery stenosis and any continuous variable. The final model was obtained by 
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multivariable logistic regression analysis using a backward elimination procedure 
variables with the p-value for removal set at 0.1.  
Model evaluation 
The reliability of predictions by the model was tested by the Hosmer-Lemeshow 
goodness-of-fit test. The predictive ability of the model was assessed by the area under 
the receiver operating characteristic curve (AUC). The internal validity of the model was 
evaluated by the use of bootstrapping. For this, the multivariable logistic regression 
analysis with backward elimination of variables was replicated in 200 bootstrap 
samples. The AUC of each of these 200 models was compared to the AUC of the model 
in the original dataset. The mean absolute difference between these 200 values and the 
value resulting from the original dataset is an estimation of the optimism in the fit of the 
model and the AUC was adjusted for this estimation.7 We estimated the degree of 
overfitting likely to be present by the method by Van Houwelingen and Le Cessie8 and 
adjusted the regression coefficients accordingly. The rationale behind this adjustment is 
to improve the calibration of the model, i.e. to prevent low predictions from being too low 
and high predictions from being too high.7 To enable the use of the model in practice, 
the predictor variables were given weighted scores based on their regression 
coefficients. We determined the predicted probability of renal artery stenosis for all 
possible sum scores.9  
Missing data 
Missing values of candidate predictors were handled by multiple imputation from an 
imputation model that contained the dependent variable (presence or absence of renal 
artery stenosis), all candidate variables that were intended to enter into the prediction 
model and factors that were related to the occurrence of missing data.10 For any missing 
value, ten values were drawn from the posterior distribution of the imputation model.11 
Thus, ten completed data sets were created. All multivariable analyses were conducted 
on each of the ten datasets and the results and standard errors were combined.12,13 
Analyses were performed with SPSS 11.5, StataSE 8.0 and Amelia.14  
 
This study was approved by the Institutional Review Board of the Maastricht University 
Hospital. 
Results 
Between October 1998 and October 2003, 372 patients had undergone renal 
angiography, of whom 326 were judged eligible for this study. Main reasons for 
exclusion were: age lower than 18 or higher than 75 years, absence of clinical clues 
suggesting renovascular hypertension and a history of untreated renal artery 
abnormalities. Angiography revealed atherosclerotic renal artery stenosis of 50% or 
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more in 49 patients, FMD in fourteen patients and a combination of atherosclerotic and 
fibromuscular abnormalities in one patient.  
 
The prevalence of the clinical clues in the study population is presented in Table 2.1. 
The prevalence of most clues was rather low, i.e. below 25%. Criteria which were more 
frequently observed were “hypertension refractory to appropriate treatment”, “sudden 
onset or worsening of hypertension”, “unexplained impairment of renal function”, “raised 
serum cholesterol” and “left ventricular hypertrophy”. Patients with renal artery stenosis 
presented with more inclusion criteria and also a higher number of clues according to 
the Working Group on Renovascular Hypertension than patients with patent arteries 
(mean±SD: 4±2 vs. 3±2 , p<0.0001 and 2±1 vs. 1±1, p<0.0001, respectively).  
 
The results of univariable analysis of all candidate predictors are presented in Table 2.2. 
Statistitical significant predictors (p<0.05) of renal artery stenosis were: age, body mass 
index, pulse pressure , smoking, serum creatinine, and the criteria “unexplained renal 
impairment or renal disease”, “kidney lenght difference”, “presence of a renal bruit”, 
“recent-onset hypertension” and “extra-renal atherosclerosis”. The great majority of 
variables with p>0.05 had an odds ratio near 1, indicating, in case of a dichotomous 
variable, that these risk factors appear with the same frequency in patients with and 
without renal artery stenosis. 
 
Table 2.2 also shows the results of the multivariable analysis. The model obtained with 
backward elimination (simplified model) contained only six predictors of renal artery 
stenosis: age, pulse pressure, smoking, “kidney length difference”, “recent onset 
hypertension” and “extra-renal artherosclerosis”. The AUC of the full model was 0.81 
(95%-CI 0.76-0.87), that of the simplified model 0.79 (95%-CI 0.73-0.85). The small 
difference between these values suggested that the variables that were deleted during 
stepwise variable selection did not contribute much to the predictive ability. The 
bootstrap adjusted AUC of the simplified model was 0.75.  
 
The model fitted well according to the Hosmer-Lemeshow goodness-of-fit test (p=0.57). 
Figure 2.1 presents the agreement between the predicted probability of renal artery 
stenosis by the simplified model versus the observed probability of renal artery stenosis. 
The overall calibration was quite good, except in the highest categories (with predicted 
probabilities >70%, 2% of the study group), where predicted probabilities were lower 
than observed probabilities. The AUC for patients with atherosclerotic disease was 
higher than for patients with FMD (0.83 (95%-CI 0.76-0.89) versus 0.68 (95%-CI 
0.59-0.78)). To obtain the predictor “kidney length difference”, the patients will have to 
undergo additional testing. In a post-hoc analysis, we determined the AUC of the model 
without this predictor. The AUC was 0.77 (95%-CI 0.71-0.89) and 0.74 after bootstrap 
correction. (Figure 2.1). 
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Table 2.2 Predictive ability of clinical clues. 
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Figure 2.1 The agreement between the predicted and the observed probabilities of renal artery 
stenosis in patients suspected of renovascular hypertension. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Agreement between the predicted probabilities of renal artery stenosis (the horizontal axis) and 
observed probabilities of renal artery stenosis (on the vertical axis). The thick line represents the 
smoothed calibration curve of predictions when information regarding renal lengths is available, the 
dotted line when this information is not available. 
 
 
To obtain the predicted probability for renal artery stenosis in a patient, the first step is 
to add the scores that are associated with the level of the predictors (Table 2.3).  
 
Table 2.3 Sum score. 
Predictor Number of points 
Age <30  -2 
 30 - 39  0 
 40 - 49  2 
 50 - 59  4 
 60 - 69  6 
 70 - 75  8 
Pulse pressure <50  -1 
 50 - 59  0 
 60 - 79  1 
 80 - 99  2 
 100 - 109  3 
 >110  4 
Current or former smoker? no  0 
 yes  5 
Recent onset of hypertension no  0 
 yes  5 
Number of vascular beds with manifest   0  0 
atherosclerosis (excluding renal vasculature)   1  2 
 >2  4 
>10% difference between length of the kidneys as absent  0 
determined by renal ultrasound ? present  6 
   unknown  0 
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This sum score corresponds to a predicted probability as is presented in the Figure 2.2. 
The probability plot can be used when renal ultrasound is part of routine work-up and 
when it is not . One may decide to perform angiography only when the probability of 
renal artery stenosis is higher than a certain threshold value. Table 2.4 represents 
sensitivity, specificity, the number patients of that will be referred for angiography and 
the number of cases with renal artery stenosis that are missed for various cut-off points. 
 
 
Figure 2.2 Predicted probability of renal artery stenosis in patients suspected of renovascular 
hypertension. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to obtain the risk estimate of a patient on renal artery the relevant numbers 
in the right column of Table 2.3 should be added. For each sum of scores, the 
probability of renal artery stenosis, as derived by logistic regression analysis 
(simplified model, Table 2.2), is plotted against the probability of renal artery 
stenosis. When a patient did undergo renal ultrasound, the bold curve applies, if not, 
the dotted one should be used. The probability can also by calculated with the 
following formula:  
eS 
 
eS +1 
 
In case ultrasound performed was: S= -4.99 + 0.033*age + 0.010*pulse pressure + 
0.75*smoking behaviour + 0.80*recent onset of hypertension + 0.33*extra-renal 
atherosclerosis + 0.94*kidney length difference >10%  
 
In case ultrasound was not performed: S= -4.738+ 0.032*age + 0.010*pulse 
pressure + 0.84*smoking behaviour + 0.77*recent onset of hypertension + 
0.33*extra-renal atherosclerosis 
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Table 2.4 The consequences of several threshold values for the predicted probability at which 
angiography is preformed. 
Predicted 
probability (%) 
Sensitivity (%)
  
Specificity (%)
  
Reduction of 
angiographies (%) 
Missed cases of renal 
artery stenosis (%) 
>0  100  0  0  0 
>10  93  38  38  11 
>20  74  69  60  29 
>30  49  85  74  43 
>40  29  91  86  59 
>50  20  97  89  69 
>60  10  99  95  81 
>70  5  100  98  90 
Discussion  
We evaluated the ability of several established and widely quoted clinical clues to 
predict the presence of renal artery stenosis in a population of consecutive patients 
suspected of having renovascular hypertension. Although the number of positive criteria 
was higher in patients with renal artery stenosis than in those without, most of these 
clues had only limited predictive value. Reasons for this finding were a low prevalence 
of these clues, lack of ability to discriminate between patients with and without renal 
artery stenosis, or lack of additional information over and above other patient 
characteristics. For example, several previous studies identified an abdominal bruit as 
an important predictor,5,16-19 a finding which we could confirm in univariable analysis. 
However, when all potential predictors were tested simultaneously using multivariable 
analysis, the odds ratio dropped from 3.26 to 1.23, and was no longer statistically 
significant. Only three clues, namely a length difference between the kidneys exceeding 
10%, as diagnosed by renal ultrasound, the presence (and extent of) extra-renal 
atherosclerosis and onset of hypertension within two years, proved to be independent 
predictors of renal artery stenosis. A model that combined these three clues with 
information regarding age, pulse pressure and smoking had a reasonable predictive 
value. The criterion “kidney length difference” involves testing that may not be part of 
the diagnostic work-up of renovascular hypertension in all centers. When this 
information is not available, the predictive ability of the model is lower but still fairly 
good. 
 
The difficulty of the diagnostic work-up of patients in whom renovascular hypertension is 
suspected, is well reflected by the amount of articles proposing diagnostic strategies. 
The most popular ones is probably the Mann-Pickering strategy. Applying the 
classification by Mann and Pickering to our study group, led to 172 patients (among 
whom 45 with renal artery stenosis) with a high index of clinical suspicion, 118 with a 
moderate index (among whom twelve with renal artery stenosis) and 36 (among whom 
seven with renal artery stenosis) with a low index of suspicion. Mann and Pickering 
state that patients with a high index of clinical suspicion should undergo angiography, 
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patients with a moderate index of clinical suspicion should undergo non-invasive 
screening, and patients with a low index should not be tested any further. We assumed 
a sensitivity of 69% and a specificity of 91% for the non-invasive screening test, as was 
found for the best non-invasive screening test in a recent comparative study between 
computed tomography angiography and magnetic resonance angiography.1 In that 
case, digital subtraction angiography would have been performed in 190 patients, and 
would have detected 53 out of the 64 cases with renal artery stenosis. This diagnostic 
strategy would have a sensitivity of 83% and a specificity of 48% in our study 
population, while reducing the number of angiographies from 326 to 190, a reduction by 
42%. Using the prediction model as developed in the present study, a sensitivity of 83% 
is associated with a specificity of 59%. In other words, to detect the same number of 
stenoses as with the Mann and Pickering strategy, 160 instead of 326 angiographies 
would have to be performed, a reduction by 51%. The major disadvantage of the Mann 
and Pickering strategy is the incorporation of a screening test, with associated costs and 
relatively low gain in the absence of satisfactory noninvasive tests. If a better screening 
test would become available, the specificity of the strategy on its whole would rise.  
 
Another well-known model is the prediction rule developed in the DRASTIC-study.18 The 
use of this prediction rule is restricted to patients with either treatment resistant 
hypertension or an increase in serum creatinine during therapy with an ACE-inhibitor. In 
this respect, we believe that the prediction rule developed in this study better 
approaches common clinical practice since it is applicable to all patients who have 
hypertension and at least one clinical clue pointing to renal artery stenosis. For 
example, it is likely that a clinician will suspect renovascular hypertension in a smoking 
65-year old male patient with a renal bruit even when his blood pressure is controlled 
with two drugs. Moreover, our study enabled evaluation of the use of potential predictors 
that were not investigated in the model of the DRASTIC-investigators. An overview of 
differences between our model and the DRASTIC rule as well as the Mann Pickering 
strategy is presented in Table 2.5. 
 
There are more studies on the predictive value of clinical clues for the presence of renal 
artery stenosis, but the implementation of findings from these studies is hampered by 
the use of screening tests with sub-optimal characteristics,20-23 the development on 
small data-sets17,24 or lack of proof of renal artery stenosis by digital subtraction 
angiography.24,25 
 
The present study also has limitations. First of all, a relatively high number of patients 
did not undergo renal ultrasound (41%) and/or echocardiography (30%). Renal duplex 
ultrasound was abandoned as a screeningtest during the study period because of its 
low sensitivity for the diagnosis of renal arty stenosis and the amount of missing data 
was therefore expected. However, we dealt with these missing values using a statistical 
technique that gives unbiased estimates of the odds ratio’s assuming that the probability 
of missing data on a certain variable is unrelated to the value of that certain variable 
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after controlling for observed variables, in other words when data are missing at random 
(MAR).12 Secondly, the number of candidate predictors is relatively high in comparison 
to the number of patients with renal artery stenosis. We partly tackled this problem by 
reducing the number of candidate predictors by combining criteria that (partially) 
measure the same concepts and by adjusting the predictions by the model with 
shrinkage. Whether these measures were sufficient can only be assessed by external 
validation, but the stability of the variable selection across the bootstrap samples was 
encouraging. Since it is well known that any prediction model performs best in the data 
set it was built on, external validation is always needed. Thirdly, we acknowledge that 
preferably any test in this field should aim at detecting only those patients with renal 
artery stenosis who, at least potentially, benefit from treatment. However, adopting 
(partly) reversible hypertension as outcome in a prediction model would neglect the fact 
that revascularisation sometimes fails because of technical reasons, restenosis and the 
fact that patients may be diagnosed with renal artery stenosis at a time when secondary 
changes have already diminished the chance of a favorable outcome. Finally, all 
predictors, with the exception of “recent onset of hypertension”, seem to be related more 
to atherosclerosis than to renovascular hypertension per se, probably because 
atherosclerotic abnormalities were much more prevalent than FMD. Not surprisingly, 
therefore, the AUC for patients with atherosclerotic disease was higher than for patients 
with FMD, indicating that our model performed better at selecting patients with 
atherosclerotic than with fibromuscular abnormalities. It was not feasible, however, to 
make a distinctive model for the prediction of FMD because of its low prevalence.  
 
Our model may be used as a guide to select patients for angiography. In order to do so, 
a certain cut-off value for the predicted probability above which patients are subjected to 
angiography should be decided on. The choice of such a threshold value is always a 
trade-off between sensitivity and specificity of a test. Cutting back on specificity will 
unduly subject more patients without renal artery stenosis to digital subtraction 
angiography, while compromising on sensitivity will increase the number of patients with 
renal artery stenosis that are declared healthy. In order to make a good choice, the 
consequences of either strategy should be taken into account. Subjecting more patients 
to angiography is costly and leads in a minority of patients to serious complications like 
deterioration of renal function by contrast agents or cholesterol embolism. On the other 
hand, when the diagnosis of renal artery stenosis is missed, patients do not benefit from 
specific treatment which is in most cases revascularisation. However, whereas in terms 
of blood pressure, the value of revascularisation is well established in FMD, the merit for 
patients with atherosclerotic disease is much less clear. Until large prospective trials 
determine the benefits of revascularisation, it may be justified to give preference to 
decreasing the number of patients subjected to angiography over identifying all patients 
with renal artery stenosis. 
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Abstract 
The gold standard for the diagnosis of renal artery stenosis is digital subtraction angiography. 
However, this cannot be used routinely considering its invasive nature and costs. This study 
investigated wether intima media thickness (IMT), pulse wave velocity (PWV) and ambulatory 
blood pressure (ABPM) may contribute to the prediction of renal artery stenosis when added to 
previously identified predictors. In order to do so, IMT, PWV and ABPM were measured in 294 
consecutive patients referred to the outpatient clinic of a tertiary referral hospital who underwent 
renal angiography because of clinical suspicion on renovascular hypertension. Multivariable 
regression analysis and the area under the receiver operating characteristic curve (AUC) were 
used to evaluate the added predictive value of IMT, PWV and ABPM. IMT, PWV and ABPM were 
associated with renal artery stenosis in univariable regression analysis. The AUC of a model with 
age, office pulse pressure, smoking, onset of hypertension within two years, extra-renal 
atherosclerosis and a difference in kidney length was 0.77. When either IMT or PWV or ambulatory 
pulse pressure or any combination of the three was added, the predictive ability did not change. 
Our results do not support the use of IMT, PWV and ABPM for the assessment of risk on renal 
artery stenosis in an individual patient. 
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Introduction 
Common carotid intima media thickness (IMT) and aortic pulse wave velocity (PWV) are 
markers of structural and functional vessel wall properties. It has been shown 
repeatedly that they are associated with cardiovascular disease and traditional risk 
factors.1-5 Ambulatory blood pressure measurements (ABPM) have a higher 
reproducibility than office blood pressure measurements and predict cardiovascular risk 
over and above conventional blood pressure measurements.6 The presence of 
cardiovascular disease, however, can also be predicted relatively effectively with 
multivariable risk models composed of traditional risk factors.7 Therefore, in the 
evaluation of a novel risk marker, the additive effect should be confirmed in the 
presence of other established risk factors in a given population to determine its true 
value. Few studies have addressed this in populations at high risk for cardiovascular 
disease. 
 
The objective of the present study was to evaluate the additional value of measuring 
IMT, PWV and ABPM in a cohort of patients at high risk for cardiovascular disease. All 
patients in this report underwent renal angiography because of the clinical suspicion of 
renal artery stenosis. Previously, we developed a risk score for the diagnosis of renal 
artery stenosis in this group of patients. [van Onna M, Nelemans PJ, Kessels AGH, 
Kroon AA, Flobbe K, de Haan M, de Leeuw PW. The predictive value of clinical clues for 
the diagnosis of renal artery stenosis in clinical practice. Submitted for publication. 2007] 
We considered recognized risk factors for cardiovascular disease as well as established 
clinical clues for renovascular hypertension as candidate predictors. Six predictors were 
identified: age, office pulse pressure, smoking, onset of hypertension within two years, 
extra-renal atherosclerosis and a difference in kidney length exceeding 10% (as 
measured by renal ultrasound). This model discriminated well between patients with and 
without renal artery stenosis in a group of consecutive patients who underwent renal 
angiography. Yet, we hypothesized that the precision of predictions could be improved 
by adding IMT, PWV and ABPM because they might provide a more refined measure of 
extra-renal atherosclerosis and pulse pressure respectively. 
Materials and methods 
Patients 
As of April 1999, all patients referred to our outpatient clinic for work-up of their 
hypertension, undergo carotid ultrasonography, PWV measurement and ABPM after 
their antihypertensive medication has been discontinued for three weeks. In a subset of 
these patients renal angiography is performed eventually. Previously, we have studied 
the clinical characteristics of our angiography patients and constructed a prediction 
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model for the diagnosis of renal artery stenosis. [van Onna M, Nelemans PJ, Kessels 
AGH, Kroon AA, Flobbe K, de Haan M, de Leeuw PW. The predictive value of 
established clinical clues for the diagnosis of renal artery stenosis in clinical practice. 
Submitted for publication. 2007] In short, patients were judged eligible for that study if 
they were between 18 and 75 years of age, had a diastolic blood pressure equal to or 
exceeding 95 mmHg, and had one or more clinical characteristics suggestive of the 
presence of renovascular hypertension8,9 and/or signs commonly associated with renal 
artery disease. Suspicion of renovascular hypertension had to have been the main 
indication for angiography. We retrieved clinical files from these patients and collected 
data using standardized forms. The present report comprises all subjects that 
contributed to the prediction model and underwent angiography between April 1999 and 
October 2003. Only examinations of B-mode ultrasonography, aortic pulse wave 
velocity and ambulatory blood pressure measurements that were performed within a 6 
month-period before renal angiography were considered. 
B-mode ultrasonography 
B-mode ultrasound examination is performed with an ultrasound apparatus with a 
transducer frequency of 7.5 Mhz and a three-lead ECG modality (Sigma 44, Kontron 
Instruments). The IMT of the right and left common carotid artery (CCA) is measured 
with the patient in recumbent position. The CCA is scanned longitudinally and the 
lumen-intima and the media-adventitia interfaces of the far wall are visualized. We 
obtain an image in the end-diastolic phase of the cardiac cycle (R-wave on the ECG) 
and store it on a personal computer. Before June 2001 only one image per side was 
acquired, thereafter, we have depicted the CCA in four angles per side (90˚, 120˚, 150˚, 
180˚ on the right side and 270˚, 240˚, 210˚, and 180˚ on the left side respectively) and 
thus four images per side are obtained. On each image, the mean distance between the 
lumen-intima and the media-adventitia interfaces is measured using an automated edge 
detection algorithm (M’Ath 2.0.1; Metris) in the ten mm segment proximal to the 
bifurcation of the carotid artery. For the current analysis, we averaged mean IMT of the 
left and right CCA. 
Pulse wave velocity 
Carotid-femoral PWV was measured by an automated device (Complior, Colson) after 
at least fifteen minutes rest with the patient in supine position. With the use of this 
apparatus, the technician obtains transcutaneously waveforms at the right common 
carotid artery and at the right femoral artery and the time delay (dt) is assessed between 
the feet of the waveforms. At least ten measurements with a good upstroke are 
acquired. The distance (D) between the recording sites is measured. The PWV is 
calculated automatically by the device as D/dt. 
 Value of IMT, PWV and ABPM ⏐37 
Ambulatory blood pressure monitoring 
Ambulatory blood pressure is measured with either Spacelabs 90207, Spacelabs 
90217-b (Spacelabs Medical, Inc.) or the TM-2430 (A & D Engineering, Inc.) during 
24 hours, with the cuff applied to the non-dominant arm. Blood pressure is measured 
every fifteen minutes during daytime (07:00 a.m. – 11.00 p.m.) and every 30 minutes 
during night hours (11:00 p.m. – 07:00 a.m.) Patients are instructed to adhere to their 
normal daily activities and sleeping hours. 
Statistical analysis 
Since deleting cases with missing data potentially causes bias, we replaced missing 
values by multiple imputation. Multiple imputation involves imputing values for each 
missing item and creating m completed data sets. Across these completed data sets, 
the observed values are the same, but the missing values are filled in with different 
imputations to reflect uncertainty. For the purpose of imputation, we selected all 
variables that were intended to enter analyses, and factors that were related to the 
occurrence of missing data.10 We created m=20 datasets with an Expectation-
Maximization algorithm with importance sampling.11  
 
We investigated the relationships between IMT, ABPM and PWV with bivariate 
correlation analysis according to Pearson. Differences between the patient groups were 
tested with a two-sided t-tests or Chi-Square-tests. We explored the predictive ability of 
IMT, PWV and ABPM for the diagnosis of renal artery stenosis with univariable logistic 
regression analysis. We tested whether IMT, abdominal PWV and ABPM improved the 
prediction of renal artery stenosis by use of multivariable logistic regression analysis. In 
order to do so, we produced five models: 1. IMT added to the variables of the prediction 
model, 2. PWV added to the variables of the prediction model, 3. Ambulatory PP instead 
of Office PP in the model 4. IMT, PWV and ABPM added to the variables of the 
prediction model. 5. IMT and PWV added to the variables of the prediction model. The 
additive value was evaluated by the change in the –2 Log Likelihood and the (change 
in) the area under the curve of the receiver operating characteristic curve (AUC).12,13 
Analyses were performed with SPSS 11.5, StataSE 8.0 and Amelia.14 
Results 
Between April 1999 and October 2003, 294 eligible patients had undergone renal 
angiography. Results of IMT, PWV and ABPM within the 6 months before angiography, 
were not available in respectively 12%, 29% and 6%. For various reasons, some people 
underwent investigations while still being on antihypertensive medication; since this will 
interfere with the results of PWV and ABPM, these measurements were not further 
considered (22%). Angiography showed abnormalities in 79 patients of whom 29 had 
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<50% atherosclerotic renal artery disease, 38 atherosclerotic renal artery stenosis of 
50% or more, eleven patients fibromuscular dysplasia and one a combination of 
atherosclerotic and fibromuscular abnormalities. A patient was considered to have 
significant renal artery stenosis when the angiogram showed fibromuscular dysplasia or 
>50% luminal reduction in case of atherosclerotic disease. Thus, analyses were 
performed on 50 patients with and 244 without renal artery stenosis. 
 
Table 3.1 shows characteristics of patients with and without renal artery stenosis. 
Patients with renal artery stenosis presented with a worse cardiovascular risk profile: 
they were older, had a higher systolic and a lower diastolic blood pressure, a higher 
serum creatinine and had more often wide-spread atherosclerosis. Table 3.1 also shows 
that patients with renal artery stenosis had a higher IMT, a higher aortic PWV and 
higher ambulatory pulse pressure. Noticeably, ambulatory blood pressure 
measurements were performed while patients were off blood-pressure lowering drugs 
as opposed to the office measurements which were taken while patients used their 
medication. Still, ambulatory blood pressure measurements were lower in both patients 
with and without renal artery stenosis. 
 
Table 3.1 Patient characteristics 
Patient characteristic 
   
No abnormalities 
(n=244) 
Renal artery stenosis
(n=50) 
p 
  
Age (years)   53 ± 12  58 ± 11 0.002 
Male gender (%) 57 58 0.851 
Body mass index (kg/m2)  28 ± 5  26 ± 4 0.004 
Office systolic blood pressure (mmHg)   171 ± 28  178 ± 20 0.035 
Office diastolic blood pressure (mmHg)   100 ± 16  95 ± 12 0.041 
Office pulse pressure (mmHg)   71 ± 23  83 ± 20 0.001 
Hypercholesterolemia (%) 32 46 0.057 
Diabetes mellitus (%) 11 10 0.891 
Smoking (%) 63 88 0.001 
Creatinine (µmol/l)   100 ± 37  113 ± 37 0.029 
Kidney volume difference (%) 15 32 0.008 
Recent onset hypertension (%) 28 44 0.043 
Extra-renal atherosclerosis   <0.0001 
    1 site (%) 22 28  
    2 sites or more (%) 9 30  
Ambulatory systolic blood pressure (mmHg)  165 ± 23  168 ± 17 0.484 
Ambulatory diastolic blood pressure (mmHg)  103 ± 15  98 ± 12 0.057 
Ambulatory pulse pressure (mmHg)  63 ± 16  70 ± 14 0.013 
Intima media thickness (mm)  0.68 ± 0.12  0.73 ± 0.11 0.012 
Aortic pulse wave velocity (m/s)  13.7 ± 3.8  15.6 ± 4.7 0.007 
 
Correlations between ABPM, IMT and PWV are depicted in Table 3.2. Of the blood 
pressure indices, pulse pressure correlated best with IMT and PWV with correlation 
coefficients of 0.36 and 0.46 respectively (p<0.0001 for both). IMT and PWV were also 
statistically significantly correlated with each other (r=0.38, p<0.0001).  
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Table 3.2 Matrix of correlations between mean 24-hour ambulatory blood pressure, intima media 
thickness of the common carotid artery and aortic pulse wave velocity in 144 patients 
who underwent all three investigations. 
Test aDBP aPP aMAP IMT PWV 
aSBP 0.77c  0.75c 0.93c  0.23b   0.35c 
aDBP  0.16 0.94c 0.00 0.08 
aPP   0.46c  0.36c   0.46c 
aMAP    0.13   0.22b 
IMT       0.38c 
a p<0.05, b p<0.01, c p<0.001 aSBP denotes ambulatory systolic blood pressure, aDBP ambulatory 
diastolic blood pressure, aPP ambulatory pulse pressure, aMAP ambulatory mean arterial 
pressure, IMT intima media thickness and PWV aortic pulse wave velocity. 
 
Univariable analysis of predictors with renal artery stenosis are presented in Table 3.3. 
Besides the predictors we identified in previous research (age, pulse pressure, smoking 
behaviour, length difference between the kidneys, onset of hypertension within two 
years and extra-renal atherosclerosis), also ambulatory PP, IMT and aortic PWV were 
predictors of renal artery stenosis. Univariable diagnostic odds ratio’s for 24-hour 
ambulatory blood pressure and office blood pressure were similar. 
 
Table 3.3 Multivariable analysis of original prediction model and suppplemented models. 
Predictor Univariable Multivariable 
  
  
 
OR (95%-CI) 
Model 1 
OR (95%-CI) 
Model 2 
OR (95%-CI) 
Model 3 
OR (95%-CI) 
Age (per 10 years)  1.55 (1.17-2.04) 1.35 (0.96-1.89) 1.40 (1.00-1.95) 1.20 (0.81-1.78) 
Office pulse pressure (per 10 mmHg)  1.25 (1.09-1.38) 1.18 (1.01-1.39) - 1.16 (0.99-1.37) 
Smoking   4.29 (1.76-10.45) 3.61 (1.41-9.28) 3.66 (1.42-9.40) 3.61 (1.38-9.48) 
Kidney volume difference  2.64 (1.32-5.26) 2.69 (1.24-5.85) 2.94 (1.33-6.50) 2.73 (1.24-6.01) 
Recent onset hypertension   1.92 (1.03-3.57) 2.51 (1.23-5.11) 2.63 (1.28-5.41) 2.49 (1.21-5.08) 
Extra-renal atherosclerosis  2.32 (1.56-3.43) 1.61 (1.03-2.51) 1.55 (0.98-2.45) 1.56 (0.98-2.48) 
Ambulatory pulse pressure (per 10 mmHg)  1.26 (1.05-1.45) - 1.22 (0.97-1.54) - 
Intima media thickness (per 0.1 mm)  1.40 (1.07-1.67) - - 1.14 (0.80-1.42) 
Aortic pulse wave velocity   1.11 (1.04-1.20) - - 1.04 (0.57-3.98) 
Area under the ROC-curve   0.78 (0.71-0.84) 0.77 (0.70-0.84) 0.78 (0.72-0.85) 
Multivariable analysis of the original prediction model (model 1) and of the prediction model when 
office pulse pressure was replaced by ambulatory pulse pressure (model 2) and when 
supplemented by intima media thickness and aortic pulse wave velocity (model 3). 
 
Table 3.3 shows that the predictive ability of most univariable predictors was attenuated 
in multivariable analysis. The AUC of the original model was 0.78 (0.71-0.84) (Table 3.3, 
Model 1). When either ambulatory pulse pressure or IMT or PWV was added, the 
predictive ability did not change (AUC was 0.77 (0.70-0.84), 0.78 (0.71-0.85), and 0.78 
(0.71-0.85) respectively (Table 3.3, Model 2)) and the same was true when both IMT 
and PWV were added (AUC 0.78 (0.72-0.85)). (Table 3.3, Model 3). The addition of IMT 
and PWV did not improve model fit (change of the –2 Log Likelihood of –1.58, p>0.05). 
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Discussion  
We have demonstrated that intima media thickness, pulse wave velocity and ambulatory 
pulse pressure were interrelated in a population at high risk for cardiovascular disease. 
Yet, since the correlation coefficients did not exceed 0.5, their determinants are 
presumably, at least in part, different. All three additional investigations were associated 
with renal artery stenosis, but their contribution to a correct diagnosis of renal artery 
stenosis was negligible in the presence of other risk predictors. 
 
Our findings confirm the results of previous evaluations of the additional value of 
structural and functional vessel wall properties in the diagnosis of cardiovascular 
disease in both high15,16 and low risk populations.1,17-19 Herrington et al.15 studied the 
predictive value of lower extremity arterial compliance in patients suspected of coronary 
artery stenosis. When added to established risk factors like age, sex, tobacco use, (the 
presence of) hypertension, hyperlipidemia, diabetes mellitus and obesity, the AUC 
changed from 0.73 to 0.74. Held et al.16 studied a cohort of patients with stable angina 
pectoris and found that, whereas IMT predicted the combined endpoint of 
cardiovascular death, myocardial infarction and cardiac revascularization, it did not 
when classical risk factors were accounted for. The investigators of the Atherosclerosis 
Risk in Communities (ARIC) study17 investigated incident coronary heart disease in the 
general population, subdivided according to race (black or white) and gender. On 
average, the AUC rose with 0.1 when IMT was added to a model containing age, 
cholesterol blood pressure, smoking behavior, antihypertensive medication and 
diabetes. In the Rotterdam study18 the AUC for the predictions of incident myocardial 
infarction and stroke in the general population rose from 0.72 to 0.75 when IMT was 
added. Störk et al.19 found that the AUC for prediction of incident cardiovascular 
mortality in independently living men over 70 years, rose from 0.71 to 0.77 when both 
carotid plaque score and arterial stiffness were added to a model containing age, 
medical history, medication-use, body mass index, blood pressure and lipid profile. The 
improvement of the AUC when carotid stiffness was added to a model already 
containing carotid plaque score was small (0.75 to 0.77), IMT did not improve the 
predictive ability. IMT independently predicted incident myocardial infarction and stroke 
in the Cardiovascular Health Study.1 The additional predictive value, however, was not 
quantified by means of change in AUC. The multivariable OR of an increase of the 
maximum common carotid IMT with 0.20 mm was, however, only 1.27 and this may be 
comparable to our results although we measured mean IMT and not maximum IMT; we 
found an multivariable OR of 1.14 per 0.10 mm increase which is equivalent to an OR of 
1.29 per 0.20 mm increase.  
 
The European Society of Hypertension and the European Society of Cardiology have 
recommended the measurement of IMT in patients with hypertension to improve risk 
stratification in their guidelines for the management of arterial hypertension.20 They 
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considered pulse wave velocity of importance, but they acknowledged that it should be 
tested further to establish the predictive value. Our results and results from previous 
studies do not sustain the guideline on this point. The presence of cardiovascular 
disease can be predicted relatively effectively with multivariable risk models composed 
of traditional risk factors: in diverse populations with diverse outcome measures the 
average AUC is about 0.72 in literature.15-19 and in our model, in which risk factors 
specific for renal artery stenosis were considered, the AUC was 0.78. IMT and arterial 
stiffness measurements did not increase the predictive ability substantially in any of 
these studies. Therefore, our results and results from previous studies do not support 
the use of IMT and PWV for risk stratification of an individual patient. 
 
Several issues should be considered in order to fully appreciate our findings. First, the 
outcome under study was renal artery stenosis which was caused by atherosclerosis in 
78% and by fibromuscular dysplasia in 22% of the patients. Whereas PWV and IMT 
have been associated with atherosclerotic disease at multiple sites in numerous studies, 
to our knowledge only one such report is available in patients with renal fibromuscular 
dysplasia without carotid artery involvement.21 That study demonstrated an association 
of both common carotid intima media thickness and carotid distensibility with 
angiographically documented renal artery fibromuscular dysplasia. Still, this should be 
kept in mind when comparing our data with studies that used only atherosclerotic 
manifestations like myocardial infarction and stroke as outcome measures. Secondly, a 
relatively high number of patients did not undergo all three additional investigations. Yet, 
we dealt with these missing values using state-of-the-art statistical techniques that 
would be 98% efficient even when 50% of the entire dataset would have been missing.22 
Thirdly, our evaluation is confined to the predictive value of IMT, PWV and ABPM. The 
value of ABPM is beyond dispute in measuring the “actual blood pressure” for the 
diagnosis of hypertension and evaluation of treatment. IMT is a valuable intermediate 
outcome measure that may increase efficiency and feasibility of randomized clinical 
trials.23 For the individual patient, however, the potential value of IMT and PWV 
assumes that they parallel risk on cardiovascular disease and that favorable changes in 
these measures indicate a reduction in risk, which has not been proven yet.24 
Conclusions 
Our results indicate that for the prediction of the presence of renal artery stenosis, more 
sophisticated measurements (ABP, IMT, PWV) do not perform better than rather crude 
measurements (anamnesis, medical history, physical examination, office blood 
pressure). 
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Abstract 
It is largely unknown to what extent genetic abnormalities contribute to the development of 
atherosclerotic renal artery disease. Among the potential candidate genes, those of the renin-
angiotensin system and the endothelial nitric oxide synthase (eNOS) rank high, because of their 
importance in the atherosclerotic process. We investigated the association of polymorphisms in 
these genes (the angiotensinogen Met235Thr, the angiotensin converting enzyme 
insertion/deletion, the angiotensin II type 1 receptor A1166C and the eNOS Glu298Asp) with the 
presence or absence of atherosclerotic renovascular disease, in 456 consecutive hypertensive 
patients referred for renal angiography on the suspicion of renovascular hypertension. Non-
diseased normotensive (n=200) and hypertensive (n=154) patients from a family practice served as 
external controls. Renal artery disease was present in 30% of our angiography group. The Asp-
allele of the endothelial nitric oxide synthase Glu298Asp polymorphism was associated with 
atherosclerotic renal artery stenosis with an odds ratio (95% confidence interval) of 1.44 
(1.00-2.09) versus hypertensives with angiographically-proven patent arteries, of 1.89 (1.24-2.87) 
versus hypertensive family practice controls and of 2.09 (1.29-3.38) versus normotensive family 
practice controls. However, this allele differed also significantly between patients with patent renal 
arteries and both normotensive and hypertensive controls. No differences were found with respect 
to the other genetic polymorphisms. 
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Introduction 
Atherosclerotic renal artery stenosis (ARAS) is a relatively common cause of secondary 
hypertension.1 Nowadays, most investigators consider this abnormality to be part of a 
generalized atherosclerotic complex with an etiological background similar to extrarenal 
atherosclerosis.  
 
Although it is still largely unknown if and to what extent genetic abnormalities contribute 
to the development of this disease, polymorphisms in genes of the renin-angiotensin 
system rank high among the potential candidates. For instance, the D-allele of the 
insertion/deletion variant of the angiotensin converting enzyme (ACE) gene has been 
associated with atherosclerotic disease,2,3 and it is conceivable that this is true also for 
ARAS. Another genetic variant that could have a bearing on the renal vasculature is the 
angiotensin II type 1 receptor A1166C (AT1R A1166C) polymorphism. Patients 
homozygous for the C-allele of this polymorphism have increased sensitivity to 
angiotensin II4 and may, in combination with the DD genotype of the ACE gene, run an 
increased risk of cardiovascular complications.5 Finally, the angiotensinogen Met235Thr 
(AGT Met235Thr) polymorphism is of interest because the Thr-allele of this 
polymorphism is associated with high plasma levels of AGT and increased 
responsiveness to angiotensin II.6 
 
In addition to studies of angiotensin II and its precursors, many studies have highlighted 
the importance of endothelium-derived nitric oxide (NO) in inhibiting atherosclerotic 
disease and the possibility that impairment of endothelial NO production promotes 
atherosclerosis. NO is produced by endothelial nitric oxide synthase (eNOS). The gene 
encoding eNOS has a G to T polymorphism at position 894 leading to substitution of Glu 
by Asp at codon 298 of the eNOS protein. The mutant allele is associated with a 
reduced response to the eNOS inhibitor L-NMMA in healthy volunteers,7 and may be 
related to the occurrence of atherosclerotic complications.  
 
Although a few earlier studies have addressed the possible role of candidate genes 
such as the ones described above in renovascular disease,8-11 none of these have been 
performed in patient populations that were primarily selected for their risk of having 
ARAS. This is important because of the complex, yet unresolved relation between 
anatomical abnormalities and clinical symptoms of renovascular disease.12 In the 
present study, therefore, we have examined the distribution of the alleles of the above-
mentioned four candidate genes in a group of patients in whom renovascular 
hypertension was clinically suspected and who all underwent renal angiography for this 
reason. 
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Methods 
Patients 
Between January 1995 and December 2002, 456 patients referred to our outpatient 
clinic for evaluation of their hypertension underwent renal angiography. Hypertension 
was defined as systolic blood pressure above 140 mmHg or diastolic blood pressure 
above 90 mmHg on at least three occasions. All patients fulfilled one or more of the 
following criteria: persistent elevation of blood pressure despite the use of two or more 
antihypertensive drugs, accelerated hypertension, documented atherosclerotic vascular 
disease in two or more vascular beds, the presence of an abdominal bruit or 
unexplained impairment of renal function in response to antihypertensive treatment.  
 
Since mid-1996 we ask written permission from all newly referred patients to draw a 
3 ml blood sample for genetic analysis, as approved by the local Medical Ethics 
Committee. Patients who had undergone angiography between January 1995 and June 
1996 were sent a letter with the request to visit our laboratory to donate a blood sample. 
Medical history and risk factor profiles were derived from the clinical files 
 
Two experienced readers evaluated all angiographic films and reported on the site and 
nature of the aberration and the (maximum) %-stenosis via standardized forms. If the 
two estimates of the degree of stenosis differed by more than 10%, a third opinion was 
decisive. Since there is no consensus on what degree of renal artery narrowing is 
hemodynamically significant and atheromateous renal artery abnormalities are likely to 
progress in time,13 we divided our study participants into two groups: (1) patent renal 
arteries and (2) (any grade of) atheromateous renal artery disease. Patients with non-
atheromateous renal artery disease (mainly fibromuscular dysplasia) were excluded 
from analysis. 
Control populations 
Hypertensive (n=154) and normotensive (n=200) subjects from the HIPPOCRATES 
study, which is an ongoing study on cardiovascular risk and genetics in a general 
practice in Kerkrade, The Netherlands, served as control groups for the angiotensin 
converting enzyme insertion/deletion, the angiotensin II type 1 receptor A1166C and the 
endothelial nitric oxide synthase Glu298Asp genotype distributions. The details of the 
enrollment of the study participants have been published previously.14 
Genetic analysis 
Genetic analysis was performed as previously described,14 Table 4.1 shows the primers 
that were used.  
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Table 4.1 Primers used for detection of ACE I/D, AT1R A1166C, AGT Met235Thr and eNOS 
Glu298Asp polymorphisms. 
Polymorphism Primer 
ACE I/D 5’-GATGTGGCCATCACATTCGTCAGAT-3’ 
 5’-CTGGAGACCACTCCCATCCTTTCT-3’ 
  
AT1R A1166C 
  
5’-GAAGGAGCAAGAGAACATTCGACTG 
    CAGCACTTCACTACCAAATGAGAC-3’ 
 5’-CTCTGCAGCACTTCACTACCAAATGATCA-3’ 
 5’-TTTCTGACATTGTTCTTCGAGCAGCCGT-3’ 
  
AGT Met235Thr 5’-CCGTTTGTGCAGGGCCTGGCTCTCT-3’ 
 5’-CAGGGTGCTGTCCACACTGGACCCC-3’ 
  
eNOS Glu298Asp 
  
5’-AACGGTCGCTTCGACGTGCACCCCCT- 
    GCTGCTGCAGGCCCCAGATGGT-3’ 
 5’-TGCCCCTGCTGCTGCAGGCCCCAGATTAG-3’ 
 5’-TGTGGGATCAGCACCCCCTTGCAGGCCC-3’ 
 
Statistical analysis 
Statistical significance for differences in quantitative variables was tested by unpaired 
t-tests or Mann-Whitney tests when appropriate. Allele and genotype frequencies and 
other qualitative data were analysed using χ2-tests. Hardy-Weinberg equilibrium was 
tested using standard methods.15 Genetic models were further evaluated by logistic 
regression analysis, in order to “correct” for those variables (confounders), which would 
alter the interpretation of the relationship between genotype and presence of renal 
artery abnormalities when not included in the model.16 We regarded age, sex, body 
mass index, pulse pressure and renal function as potential confounders. We choose to 
regard only pulse pressure (PP) of the blood pressure parameters in our analysis 
because imputing systolic blood pressure (SBP) and diastolic blood pressure (DBP) as 
well would inevitably lead to collinearity. (Pearson’s correlation coefficients were 0.83 for 
PP vs. SBP, 0.28 for PP vs. DBP and 0.76 for SBP vs. DBP; p<0.0001 for all). We 
introduced the potential confounders independently into a model that contained 
genotype and assessed the change of the regression coefficient of the central 
determinant (genotype). The variable that led to the greatest change was retained in the 
model, provided that this change was at least 10%. The remaining potential 
confounders were then introduced again into the new model (containing genotype and 
the confounder). This was repeated until no more variables had to be retained. 
Interactions between two polymorphisms were tested in models that included the alleles 
(risk allele present or not present), the interaction between the two, and confounders 
when applicable. We assumed that both groups from the family practice contained no 
subjects with renal artery stenosis. However, previous studies suggest that secondary 
hypertension is present in about 5% of hypertensive patients and renovascular 
hypertension in approximately 1%.17-20 To the best of our knowledge no such data are 
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available on the presence of incidental renal artery stenosis in subjects without 
hypertension, but conceivably, this value is much lower. We tested the robustness of 
statistically significant results in the hypertensive group by a sensitivity analysis21 by 
modelling odds ratios after deleting 5% of the subjects in this group with all possible 
alleles. Data are expressed as mean±SD or median (interquartile range) or odds ratio 
(95% confidence interval) unless indicated otherwise. A two-sided p-value of less than 
0.05 was considered statistically significant. Statistical analyses were performed with 
SPSS 10.0 for Windows (SPSS Inc). 
Results 
Patient characteristics 
Out of the 456 patients who underwent angiography, genotyping was available in 401 
(88%). The remainder did not differ from the genotyped patients regarding 
demographics or important potential confounders. Thirty-three of the 401 patients were 
diagnosed with fibromuscular dysplasia and, therefore, excluded from analysis. Thus, 
the present report is based upon the remaining 368 subjects. In 109 (30%) of these, 
atherosclerotic renal artery abnormalities were present, among which 70 (19%) with a 
renal arterial lumen reduction of more than 50%. 
 
General characteristics of the four study groups are presented in Table 4.2. As 
expected, both normotensive and hypertensive controls from the general practice had 
lower systolic, diastolic and pulse pressures in comparison to the subjects with renal 
artery stenosis. In addition, they were more often female and had higher BMI’s 
(although not statistically significant in the normotensive group). Normotensive controls 
were slightly older than the angiography group whereas the hypertensive controls were 
a bit younger. In the angiography group, patients with renal artery stenosis (ARAS+) 
presented with a worse cardiovascular risk profile than individuals with non-diseased 
renal arteries (ARAS-): they were older, more often male, and had a longer history of 
hypertension (6 (2-17) vs. 4 (1-11) years, p=0.014). In addition they had higher pulse 
pressure, a lower estimated creatinine clearance (56±22 vs. 87±32 ml/min, p<0.001) 
and were more often hypercholesterolemic (45% vs. 29%, p=0.003) and diabetic (16% 
vs. 9%, p=0.043). Finally, they had more often suffered from atherosclerotic 
manifestations in other vascular beds (43% vs. 22%, p<0.001). 
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Table 4.2. Clinical characteristics of the study groups. 
Clinical characteristics General practice Angiography 
 normotensive hypertensive ARAS-  ARAS+ 
  p  p  p  
Age (years)  63 ± 12  0.039  57 ± 11  0.034  50 ± 13 <0.001  60 ± 10 
Sex (male/female)  95 / 105  0.003  72 / 82  0.013  137 / 122  0.031  71 / 38 
BMI (kg/m2)  27 ± 4  0.075  29 ± 6  0.007  28 ± 5 <0.001  26 ± 4 
SBP (mmHg)  133 ± 15 <0.001  158 ± 20 <0.001  176 ± 28  0.015  184 ± 28 
DBP(mmHg)  78 ± 7 <0.001  92 ± 11 <0.001  105 ± 16  0.016  100 ± 18 
PP (mmHg)  54 ± 13 <0.001  65 ± 16 <0.001  71 ± 21 <0.001  84 ± 22 
Values are presented as mean±SD. ARAS denotes atherosclerotic renal artery stenosis, p refers to 
the p-value of the test of the difference with ARAS+, BMI denotes body mass index, SBP systolic 
blood pressure, DBP diastolic blood pressure. 
Genetic analyses 
The distribution of the polymorphisms in the control populations was compatible with the 
Hardy-Weinberg equilibrium, whereas this was not the case in the angiography group 
with respect to the eNOS Glu298Asp (only ARAS) and the AGT Met235Thr 
polymorphisms. (Table 4.3) No differences in either genotype or allele frequencies were 
found between the normotensive and the hypertensive control group. 
 
Table 4.3 Distribution of genotypes in controls and angiography patients. 
Polymorphism Genotype/allele General care population n (%) Angiography n (%) 
  normotensive hypertensive ARAS- ARAS+ 
AGT Met/Met - -  104 (40.2)  38 (34.9) 
 Met/Thr - -  147 (56.5)  70 (64.2) 
 Thr/Thr - -  8 (3.1)  1 (0.9) 
 Meta - -  355 (69)  146 (67) 
 Thra - -  163 (32)  72 (33) 
ACE Ins/Ins  46 (23.3)  42 (27.3)  51 (19.5)  22 (20.2) 
 Ins/Del  98 (49.7)  68 (44.2)  132 (50.6)  58 (53.2) 
 Del/Del  53 (26.9)  44 (28.6)  78 (29.9)  29 (26.6) 
 Insa  190 (48)  154 (49)  234 (45)  102 (47) 
 Dela  204 (52)  156 (51)  288 (55)  116 (53) 
AT1R AA  104 (52.5)  79 (51.3)  140 (53.6)  52 (47.7) 
 AC  77 (38.9)  65 (42.4)  99 (37.9)  47 (43.1) 
 CC  17 (8.6)  10 (6.5)  22 (8.4)  10 (9.2) 
 Aa  285 (72)  223 (72)  379 (73)  151 (69) 
 Ca  111 (28)  85 (28)  143 (27)  67 (31) 
eNOS Glu/Glu  87 (43.5)  63 (40.9)  104 (40.2)  33 (30.3) 
 Glu/Asp  97 (48.5)  75 (48.7)  94 (36.6)  49 (45.0) 
 Asp/Asp  16 (8.0)  16 (10.4)  61 (23.6)  27 (24.8) 
 Glua  271 (68)  201 (65)  302 (58)  115 (53) 
 Aspa  129 (32)  107 (35)  216 (42)  103 (47) 
a n refers to the number of alleles. In bold genotype distributions that are not in Hardy-Weinberg 
equilibrium, ARAS denotes atherosclerotic renal artery stenosis. The AGT Met235Thr 
polymorphism was not investigated in the HIPPOCRATES study, and this information is therefore 
lacking in these subjects. 
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Normotensive controls versus patients with ARAS+ 
The distribution of the eNOS Glu298Asp polymorphism was different between 
normotensive controls and subjects with renal artery disease (χ2=17.6, p<0.0001). 
When the presence of renal artery disease was taken as dependent variable in logistic 
regression and the Glu/Glu as reference category, the odds ratios of the Glu/Asp and 
Asp/Asp genotypes were 1.33 (0.79-2.26) and 4.45 (2.13-9.30) respectively. After 
correction for pulse pressure, sex and age, the odds ratios were 1.39 (0.61-3.16) and 
5.08 (1.61-16.0) respectively. To allow comparison with data from the angiography 
group, we also performed analysis of allele frequencies, which yielded comparable 
results (Table 4.4). The frequency of the ACE ins/del and the ATR1 A1166C 
polymorphisms did not differ between controls and patients with renal artery stenosis. 
There were no interactions between the polymorphisms. 
 
Table 4.4 Logistic regression analyses: the association of eNOS Glu298Asp with renal artery 
disease. 
Model 
  
Univariable analysis 
Odds Ratio (95%-CI) 
Multivariable analysis 
Odds Ratio (95%-CI) 
Normotensive controls versus ARAS+ 
 eNOS (Asp-allele)a  1.82 (1.28-2.58)  2.09 (1.29-3.38) 
 Pulse pressureb   2.97 (2.49-3.55) 
Hypertensive controls versus ARAS+ 
 eNOS (Asp-allele)a  1.68 (1.18-2.40)  1.89 (1.24-2.87) 
 Pulse pressureb   1.73 (1.54-1.94) 
ARAS- versus ARAS+ 
 eNOS (Asp-allele)a  1.25 (0.91-1.72)  1.44 (1.00-2.09) 
 Creatinine clearanceb    0.67 (0.62-0.72) 
a Odds ratio compared to eNOS Glu 298 (=reference category); b Per 10 units ARAS- refers to 
patients with angiographically proven patent arteries, ARAS+ to those with renal artery stenosis.  
 
Hypertensive controls versus patients with ARAS+ 
Genotype frequencies of the eNOS Glu298Asp polymorphism were different between 
hypertensive controls and subjects with renal artery disease (χ2=10.2, p=0.006). When 
the presence of renal artery disease was taken as dependent variable in logistic 
regression and the Glu/Glu as reference category, the odds ratios of the Glu/Asp and 
Asp/Asp genotypes were 1.22 (0.69-2.18) and 2.88 (1.33-6.23) respectively. After 
correction for pulse pressure and sex, the odds ratios were 1.29 (0.66-2.53) and 4.17 
(1.73-10.05), respectively. Analysis of allele frequencies yielded comparable results 
(Table 4.4). This association remained even when one would assume that 5% of the 
hypertensive controls had incidental renal artery stenosis (and therefore would have had 
to be excluded from analyses). For details, please see Appendix. The frequencies of the 
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ACE ins/del and the ATR1 A1166C polymorphisms did not differ between controls and 
patients with renal artery stenosis. There were no interactions between the 
polymorphisms. 
Angiography group: ARAS- versus ARAS+ 
The genotype frequency distribution was not different with regard to the polymorphisms 
under study. Because there was no Hardy-Weinberg equilibrium with respect to the 
eNOS Glu298Asp and the AGT Met235Thr polymorphisms, we also tested differences 
in allele frequency. Again, this did not yield significant results. However, logistic 
regression analysis showed that the Asp-allele had an odds ratio of 1.44 in comparison 
to the Glu-allele on ARAS, conditionally on estimated creatinine clearance (Table 4.4). 
There were no interactions between the polymorphisms.  
ARAS- versus controls 
When the ARAS- group was contrasted with the two general care control groups, the 
Asp-allele appeared to be significantly more frequent in ARAS- than in both control 
groups (Table 4.5). 
 
Table 4.5 Logistic regression analyses: the association of eNOS Glu298Asp with differences 
between the control groups. 
Model 
  
Univariable analysis 
Odds Ratio (95%-CI) 
Multivariable analysis 
Odds Ratio (95%-CI) 
Normotensive vs hypertensive controls 
 eNOS (Asp-allele)a 1.12 (0.82-1.53) 1.33 (1.03-1.71) 
 Pulse pressureb  1.71 (1.52-1.94) 
Normotensive controls versus ARAS- 
 eNOS (Asp-allele)a 1.50 (1.14-1.97) 1.58 (1.22-2.06) 
 Pulse pressureb  2.59 (2.23-3.00) 
 Age   0.29 (0.24-0.34) 
Hypertensive controls versus ARAS- 
 eNOS (Asp-allele)a 1.34 (1.00-1.80) 1.30 (1.06-1.59) 
 Pulse pressureb  1.19 (1.10-1.29) 
a Odds ratio compared to eNOS Glu 298 (=reference category); b Per 10 units; ARAS- refers to 
patients with angiographically proven patent arteries. 
Discussion 
The objective of our study was to investigate the association of several candidate genes 
with atherosclerotic renal artery stenosis (ARAS) in a population of patients with 
hypertension and clinical clues suggesting the presence of renal artery stenosis. All 
b
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patients were subjected to angiography and the prevalence of renal artery abnormalities 
in this group was 30%. We found that patients with ARAS (ARAS+) were more often 
carrier of the Asp-allele with regard to the eNOS Glu298Asp polymorphism. Since this 
association only just reached statistical significance, we sought for additional evidence 
that the association was a genuine one. Therefore, we compared ARAS+ to two sets of 
non-diseased controls: one of hypertensive and one of normotensive subjects which 
were drawn from a family practice. Again, the Asp-allele had a significantly higher 
prevalence in patients with renovascular disease. Nevertheless, even the use of these 
control groups is not free of assumptions. The prevalence of renal artery stenosis 
among hypertensive patients in population samples is, indeed, reported to be low, 
around 1%.17-20 Still, we remain uncertain about the true prevalence of ARAS in 
controls. However, model analysis showed that our results are robust to a low 
prevalence of this condition in the control group. Furthermore, the University Hospital 
Maastricht is the nearest academic centre, but it is not the hospital closest at hand. This 
implies that patients from Kerkrade with a moderate severe clinical picture have a lower 
probability of undergoing renal angiography in Maastricht than patients with similar 
complaints from the Maastricht region, and will, therefore, be underrepresented in this 
study. Yet, we have no clues that our current controls from a general care practice are 
any different from a random selection of subjects from a general practice in Maastricht.  
 
Positive findings in an association study can be attributed to three situations. First, the 
allele itself directly affects the expression of the phenotype. Second, the allele is in 
linkage disequilibrium with another allele that is responsible for the effect. Third, the 
association is brought about by confounding or selection bias.22 Whereas the first two 
situations do not hamper the use of a polymorphism for predicting the presence of a 
condition, the third obviously does. One of the major concerns in this respect is the 
presence of selection bias. The routine use of the Hardy-Weinberg equilibrium test has 
been advocated in order to reduce false-positive findings.23 Hardy-Weinberg equilibrium 
was absent in ARAS-. We can only speculate about the explanation for this 
phenomenon, but it is very likely to be related to the fact that these patients are not truly 
healthy controls. Especially the underrepresentation of heterozygotes in ARAS- 
suggests that the presence or absence of the Asp-allele itself may have influenced the 
chance for an individual of being selected for angiography according to our criteria.  
 
Our finding of an association between the presence of renal artery stenosis and the 
eNOS Glu298Asp polymorphism should be interpreted cautiously since the prevalence 
of Asp-carriers was also higher in the ARAS- group than in the control groups. This 
implies that the ARAS- group differed from controls by an (unmeasured) variable (or 
possibly variables) that coincides with the differences in genotype distribution of the 
eNOS Glu298Asp polymorphism. Although we cannot rule out that the mutant gene 
polymorphism is associated with more severe hypertension, as both ARAS- and ARAS+ 
patients had substantially higher blood pressure than controls, this option does not fully 
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explain the data either since we accounted for blood pressure differences by logistic 
regression analysis. Although the introduction of pulse pressure in the logistic 
regression analysis may seem debatable since we cannot rule out causality (via the 
possible scenario that the Asp-allele leads to a high pulse pressure, which subsequently 
causes angiographically detectable ARAS), we found that the odds ratio on renal artery 
stenosis rose when pulse pressure was accounted for. In case of causality we would 
have expected a decrease of the odds ratio in the adjusted model. Moreover, all reports 
regarding blood pressure or presence of hypertension and the eNOS Glu298Asp 
polymorphism in Caucasians are negative.24-27 Alternatively, (differences in) the total 
burden of atherosclerosis may account for our findings. Indeed, other investigators 
previously found the eNOS Glu298Asp polymorphism to be related to the presence of 
atherosclerotic manifestations such as coronary artery disease28-30 and carotid 
atherosclerotic plaques,31 although negative reports have also been published.27 Since 
atherosclerotic renovascular disease is generally viewed upon as a local manifestation 
of systemic atherosclerotic disease, at least our data in ARAS+ are in line with these 
earlier observations. But even the results in ARAS- patients may be compatible with 
more severe atherosclerosis in these individuals. The absence of atherosclerotic lesions 
in renal arteries does not at all exclude the presence of atherosclerosis elsewhere in the 
vascular system and, indeed, 22% of the ARAS- patients had experienced signs of 
extrarenal atherosclerosis. Moreover, it is likely that normotensive and hypertensive 
patients with relatively mild forms of hypertension in a general care practice have lower 
amounts of (extra-renal) atherosclerosis than patients in an outpatient clinic of a tertiary 
referral hospital who are suspected of having renal artery stenosis. In this respect, the 
difference between ARAS- and ARAS+, namely proven renal artery atherosclerosis, 
may just be a marker of more wide-spread atherosclerosis. Indirectly, this hypothesis is 
supported by the differences between the groups regarding pulse pressure, which is 
commonly associated with the severity of atherosclerosis, although it cannot be ignored 
that ARAS+ had a far worse risk profile. Yet, since the extent of extra-renal 
atherosclerosis was not investigated in our study, we cannot exclude other 
explanations.22,23,32 
 
The most obvious candidate genes to look at when renal artery disease is the object of 
study, the ones of the renin-angiotensin system, were evenly distributed among all 
groups, at least with respect to the polymorphisms in the genes that we studied. Only 
few studies have focused on the association between ARAS and genetic 
polymorphisms and all have addressed the ACE ins/del polymorphism.8-11 Two groups 
compared the distribution of the ACE ins/del genotypes between ARAS and 
normotensive groups and found the D allele to be more prevalent in ARAS9,11. The AGT 
Met235T and the ATR1 A1166C polymorphisms were not found to be associated with 
ARAS.11 When, on the other hand, patients with ARAS were compared to patients with 
diffuse atherosclerotic disease who underwent angiography on the suspicion of aortic 
aneurysm no association was found with the ACE genotype.8 The only study that 
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compared hypertensive patients with renal artery stenosis to hypertensive patients 
without renal artery stenosis, found an overrepresentation of DD homozygotes in the 
renal artery stenosis group,10 but it must be emphasized that in only 38% of the patients 
angiography of the renal arteries was performed on the suspicion of renovascular 
hypertension. Our study is the first to examine three different polymorphisms of the 
renin-angiotensin system in hypertensive patients who were all selected according to 
the same criteria for angiography. With our standardized approach, we did not find an 
association between these genotypes and ARAS. 
Perspectives 
Taking all data together, we hypothesize that the Asp-allelle of the eNOS Glu298Asp 
polymorphism predisposes to (systemic) atherosclerosis but that the extent of the 
lesions, among which those in the renal arteries, depends also on additional risk factors. 
Considering the importance of endothelium-derived nitric oxide in atherosclerosis, our 
findings fit very well in the theoretical framework of atherosclerotic disease and merit 
further research into the mechanisms whereby altered nitric oxide production in 
conjunction with other cardiovascular risk factors may cause systemic and/or renal 
atherosclerosis. 
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Appendix 
Sensitivity analysis 
For the purpose of genetic analysis, we assumed renal artery stenosis to be absent in 
the hypertensive subjects from the general care practice. However, in the past, several 
studies reported a prevalence of secondary hypertension, among which renal artery 
stenosis, of 1-5 % in such groups.1-4 We tested the robustness of the association 
between eNOS 298Asp and renal artery stenosis by modeling OR’s when we excluded 
5% (8 subjects, 16 alleles) of the hypertensive subjects of the general care practice. 
This was done with all possible allele combinations since deleting 16 Glu allele has a 
different effect on the OR, than deleting 16 Asp alleles.  Since the control group 
consisted of 201 Glu alleles and 107 Asp allele, modeled allele numbers of the 
hypertensive controls the sensitivity analysis are thus (with 0<r<16) 201-r Glu alleles 
and 91+r Asp alleles.  
 
Odds ratios were calculated as:  
 
no. Glu-alleles (controls) / no. Asp-alleles (controls)       (201-r) / (91+r) 
no. Glu-alleles  (ARAS+) / no. Asp-alleles (ARAS+)             115/103 
 
Figure 4.I and Table 4.II show the modeled OR’s (95%-Confidence interval) for all 
values of r. Even in the unlikely event that in reality 5 % of the hypertensive patients 
from the general practice had renal artery stenosis and would therefore have to be 
omitted, the relationship we found between the eNOS Glu298Asp polymorphism and 
renal artery stenosis is still statistically significant. This holds true for the model in which 
all omitted subjects had the Asp/Asp genotype (OR 1.98 (1.38-2.85)), as well as for the 
model in which all excluded subjects had the Glu/Glu genotype (OR 1.55 (1.08-2.21)), 
and also for all intermediate possibilities. 
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Figure 4.I Sensitivity analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modelling the effect of 5% prevalence of renal artery stenosis among the hypertensives from the 
general practice, who would therefore have to be excluded, on the relationship between renal 
artery abonormalities and the eNOS Glu298Asp. 
 
 
Table 4.II Sensitivity analysis. 
ra Glub Aspc OR (95%-CI)d  
0 201 91 1.98 (1.38-2.85) 
1 200 92 1.95 (1.36-2.80) 
2 199 93 1.92 (1.33-2.75) 
3 198 94 1.89 (1.31-2.71) 
4 197 95 1.86 (1.26-2.67) 
5 196 96 1.83 (1.27-2.62) 
6 195 97 1.80 (1.26-2.58) 
7 194 98 1.77 (1.24-2.54) 
8 193 99 1.75 (1.22-2.50) 
9 192 100 1.72 (1.20-2.46) 
10 191 101 1.69 (1.18-2.43) 
11 190 102 1.67 (1.17-2.39) 
12 189 103 1.64 (1.15-2.35) 
13 188 104 1.62 (1.13-2.31) 
14 187 105 1.60 (1.12-2.28) 
15 186 106 1.57 (1.10-2.25) 
16 185 107 1.55 (1.08-2.21) 
Modelling the effect of 5% prevalence of renal artery stenosis among the hypertensives from the 
general practice, who would therefore have to be excluded, on the relationship between renal 
artery abonormalities and the eNOS Glu298Asp polymorphism a denotes number of deleted Glu-
alleles in the sensitivity analysis; b Number of Glu alleles in the group of hypertensives from the 
family practice; c Number of Glu alleles in the group of hypertensives from the family practice; d 
Odds ratio (95%-CI): hypertensive controls versus ARAS+. 
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Abstract 
It is generally assumed that renal blood flow is symmetric in the absence of renal artery stenosis. 
The aim of the present study was to evaluate whether this really is the case. From a group of 
consecutive hypertensive patients who had undergone renal angiography, we selected those with 
patent renal arteries. In all of them selective renal blood flow measurements (133Xenon washout 
technique) had been performed with blood sampling from aorta and both renal veins (n=148). 
Asymmetry of RBF, defined as >25% difference in renal blood flow between left and right kidney, 
was present in 51% of the patients. Subjects with and without asymmetry did not differ in age, body 
mass index, blood pressure, creatinine clearance, renal volume or activity of the renin-angiotensin 
system. The presence of asymmetry coincided with an increased rate of false-positive results on 
renal scintigraphy. Preliminary data suggest that there may be a relation between asymmetry and 
renal sympathetic nerve activity. This study demonstrates that asymmetry of renal blood flow is a 
frequent finding in severe hypertension, which may confound the results of diagnostic tests for 
renal artery stenosis. Furthermore, the present results underscore the importance of studying the 
function of both kidneys separately, since it cannot be assumed that they are functionally equal. 
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Introduction 
Evaluation of split renal function in patients with elevated blood pressure may be useful 
as a screening procedure to detect (unilateral) renal artery stenosis. Renal scintigraphy 
and, more recently, Doppler ultrasonography1 are among the tests that have been 
developed for this purpose. The implicit assumption underlying these diagnostic tests is 
that, in the absence of a hemodynamically significant renal artery stenosis, blood flow 
through the kidneys will be roughly symmetrical. Whether this is truly the case, however, 
has not been proven. 
 
In our clinic, we routinely perform selective renal blood flow (RBF) studies in all patients 
in whom renal angiography is performed on the suspicion of renovascular hypertension. 
During these investigations we frequently noted differences in renal blood flow between 
the left and the right kidney in patients without angiographic abnormalities. Whereas 
asymmetry of RBF is the hallmark of (unilateral) renal artery stenosis, inequality in RBF 
between two kidneys in patients with patent renal arteries is a more elusive 
phenomenon.  
 
To assess how often asymmetry of RBF exists in patients without renal artery stenosis 
and to search for possible determinants of this asymmetry, we have re-evaluated the 
blood flow data that were obtained in a large group of patients who had all undergone 
the same study protocol. 
Methods 
Study protocol 
Since February 1994, all patients who are referred to our clinic for evaluation of their 
hypertension (i.e. diastolic blood pressure above 90 mmHg on at least three occasions) 
are subjected to a standard diagnostic protocol. This includes renal angiography with 
selective renal blood flow measurements and arterial and renal venous blood sampling 
when patients fulfil one or more of the following criteria: hypertension despite two or 
more antihypertensive drugs, accelerated hypertension, documented atherosclerotic 
vascular disease in two or more vascular beds, the presence of an abdominal bruit or an 
unexplained impairment of renal function in response to antihypertensive treatment.  
 
For reasons of standardisation, all antihypertensive medication is discontinued for three 
weeks and patients are requested to use a sodium-restricted diet (55 mmol/24h) during 
the week preceding the study. Compliance with the diet is estimated from a 24 hour 
collection of urine. After an overnight fast, the aorta and both renal veins are cannulated 
via the femoral route and blood samples are drawn simultaneously from the aorta and 
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renal veins for determination of active plasma renin concentration (APRC) in all patients 
and angiotensin II, aldosterone and norepinephrine in subgroups as part of other study 
protocols. Subsequently, we measure selective mean renal blood flow (MRBF) by 
means of the 133Xenon washout technique2,3 as described previously.4,5 As a matter of 
routine, we start 133Xenon washout studies in the left kidney and the whole Xenon-wash-
out procedure for both kidneys is completed within approximately ten minutes. Blood 
pressure and heart rate are monitored during the MRBF measurements and no contrast 
material is administered before the flow studies have been completed. Thereafter, intra-
arterial renal angiography is performed with a commercially available digital subtraction 
system (Integris 5000; Philips Medical Systems; Best, The Netherlands). A radiologist, 
who is unaware of the results from the renal blood flow studies, evaluates the 
angiographic films.  
 
The 133Xenon washout curves are analysed off-line using a two-phase exponential 
model, after subtraction of background radiation.2,3 (GraphPad Software, Inc., San 
Diego, CA). In our hands, the 95th percentile of differences between two repeated flow 
measurements in the same kidney is 25% (mean variability of two measurements plus 
two times standard deviation), with no systematic left-right differences between the first 
and the second measurements.  
 
All patients gave written informed consent and the Maastricht University Hospital 
Medical Ethics Committee approved the study. 
Renal scintigraphy 
In the early phase of the study period, renal scintigraphy was still used as a screening 
test for renal artery stenosis. Renography was always performed with Technetium-99m 
labelled mercaptoacetyltriglycine (99mTc-MAG3), initially under baseline conditions, later 
on also after the ingestion of 50 mg of captopril. Since a recent meta-analysis did not 
demonstrate any superiority of carrying out both a baseline and a postcaptopril study 
above a postcaptopril study alone,6 results from all renographic observations were 
pooled for analysis.  
Kidney volume measurements 
As of January 1999, all patients clinically suspected of having a renal artery stenosis 
underwent computed tomography angiography (CTA) of the renal arteries on the day 
prior to intra-arterial angiography. Spiral CT examinations were performed with a CT 
Twin RTS (Elscint, Haifa, Israel) during inspiratory breath-hold with the administration of 
140 ml iohexol (Omnipaque 300; Nycomed, Oslo, Norway) and a scan delay time of 
18 seconds. The contrast-enhanced scans were obtained using a 2.7 mm collimation 
slice thickness and a pitch of 0.7. A 430-mm field of view and a 512 x 512 matrix with a 
reconstruction interval of 1.3 mm were used. CT-imaging series were only used to 
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calculate kidney volume when both kidneys were depicted completely and the subject 
had been able to hold his/her breath sufficiently long to allow acceptable imaging. The 
original images were reconstructed in a coronal plane with a 5 mm slice thickness 
without an intersection gap. On each created image the boundaries of both kidneys 
were traced manually. In cases of partial voluming, i.e. a voxel containing both kidney 
and surroundings, the segmentation line was drawn halfway. The renal volume was 
then calculated automatically by adding all voxel volumes lying within the borders of the 
kidney. 
Assay methods 
APRC was measured using a two-side immunoradiometric assay method.7 Angiotensin 
II and aldosterone were determined after extraction from plasma by radio-immunoassay 
using highly specific antibodies.8,9 A sensitive HPLC method with fluorimetric detection 
was used to determine norepinephrine concentrations.10 
Calculations and statistics 
Creatinine clearance was estimated from the Cockcroft formula.11 MRBF ratio was 
calculated by dividing flow in the kidney with the highest MRBF by that in the kidney with 
the lowest MRBF. In absence of asymmetry in MRBF, we expected a maximum 
difference between left and right kidney MRBF of approximately 25% (mean variability 
of two measurements in the same kidney plus two times the standard deviation). We 
therefore defined symmetry of MRBF as <25% difference between left and right MRBF 
and asymmetry of MRBF as >25% difference. According to this definition we divided 
study participants into two groups. Differences between the symmetry and the 
asymmetry group in patient characteristics and MRBF were analysed using unpaired 
t-tests and the Pearson Chi-Square test. Friedman’s test was applied for analysis of 
repeated measurements of blood pressure and heart rate. Since the distributions of 
MRBF ratio, kidney volume and neurohormones were not normal, nonparametric tests, 
including the Mann-Whitney U test, the Wilcoxon signed rank test and the Spearman 
analysis for correlations, were applied to test differences in these variables. The non-
parametric Chi-Square test was used to assess differences in the rate of false-positive 
results on scintigraphy. For statistical analyses, SPSS 10.0 was used. A p-value of 
<0.05 was considered statistically significant. Data with a normal distribution are 
presented as means ± SD, otherwise medians and interquartile ranges are given. 
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Results 
Between February 1994 and February 2001, combined angiography and selective renal 
blood flow studies were successfully performed in 233 patients who were without 
treatment at that time. Of these, 85 patients were excluded from analysis. Reasons for 
exclusion are listed in Table 5.1. The study group consisted of 90 males and 58 females 
with a mean age of 51±13 years. None had angiographic or biochemical abnormalities 
suggestive of secondary hypertension. Prior to study, patients were taking medication of 
2±1(range 0-5) classes of antihypertensive drugs. The withdrawal of treatment was 
tolerated well in the majority of patients, no patients were endangered. Systolic blood 
pressure at admission averaged 175±28 mmHg and the diastolic blood pressure 
105±15 mmHg. One patient had a blood pressure <135/85, but on other occasions he 
had blood pressures >140/90. The average blood pressure during 133Xenon washout 
(178±30 / 101±17) was similar to the average blood pressure at admission, and, also, 
during our measurements, mean arterial pressure and heart rate did not change (data 
not shown). The average amount of sodium in a 24 hour urine collection was 82 
(53-125) mmol. Average creatinine clearance was 93±34 ml/min; in 23 patients (16%) 
creatinine clearance was lower than 60 ml/min. 
 
Table 5.1. Reasons for exclusion of patients from the analyses. 
Reasons for exclusion Number of persons 
Renal artery abnormalities 71 
Atrophic kidney   3 
History of percutaneous transluminal renal angioplasty (PTRA)    3 
Vasovagal collapse during measurements   2 
Inaccurate positioning of catheter   1 
Other    5 
  
Total 85 
 
Renal blood flow  
Mean values for left and right MRBF in the entire group were not different (183±68 vs. 
193±78 ml/100g/min, NS). Asymmetry of MRBF was found in 75 patients (51%). Clinical 
characteristics of the symmetry and asymmetry groups are shown in Table 5.2. Groups 
did not differ with regard to age, gender, body mass index, blood pressure, heart rate 
and renal function. 
 
In patients with an asymmetric MRBF, median ratio was 1.52 (1.34-1.88) and in eleven 
(15%) cases MRBF ratio exceeded 2.00 (Figure 5.1). In subjects with symmetric MRBF, 
median flow ratio was 1.09 (1.05-1.15). In patients with asymmetric perfusion, left MRBF 
was on average lower than the right MRBF (163±68 vs. 187±90 ml/100g/min, p=0.008) 
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When patients with asymmetric flow were compared to those with symmetric flow, left 
MRBF was again lower in the former (163±68 vs. 204±62 ml/100g/min, p=0.001), while 
right MRBF was similar (187±90 vs. 200±64 ml/100g/min, NS). Although this suggests 
that asymmetry is predominantly caused by a reduction of left MRBF, right MRBF was 
lower than left MRBF in 31 out of the 75 subjects (41%) with an asymmetric flow 
pattern. The MRBF ratio, or in other words the degree of asymmetry, was similar in 
those with dominance of left and those with dominance of right MRBF (1.57 (1.35-1.87) 
vs. 1.39 (1.31-1.88), NS). The percentage distribution of renal blood flow to the cortex 
(fast component of the 133Xe-washout curve) was similar between the symmetry and the 
asymmetry group. When patients with reduced kidney function (creatinine clearance 
equal or lower than 60 ml/min) were left out of the analysis, similar findings were 
obtained with respect to asymmetry and left-right differences. 
 
Table 5.2 Clinical characteristics of hypertensive subjects with symmetric and asymmetric renal 
blood flow. 
Clinical characteristics Symmetry Asymmetry p 
Age (year)  50 ± 13  51 ± 13 NS 
Male 45 (62) 45 (60) NS 
BMI (kg/m2)  28 ± 5  28 ± 5 NS 
No. of classes of antihypertensive drugs prior to study  2 ± 1  2 ± 1 NS 
  Calcium-antagonists  44 (60) 32 (43) NS 
  β-blockers  41 (56) 39 (52) NS 
  Diuretics  27 (37) 19 (25) NS 
  Angiotensin-Converting Enzyme inhibitor  25 (34) 25 (33) NS 
  Angiotensin Type 1 receptor antagonists  14 (19) 14 (19) NS 
  Other (α-blockers, centrally-acting agents, direct vasodilators) 9 (12) 11 (15) NS 
SBPa (mmHg)  180 ± 31  177 ± 29 NS 
DBPa (mmHg)  101 ± 17  100 ± 17 NS 
HRa(beats per minute)  71 ± 15  73 ± 14 NS 
Urinary sodium (mmol/24 hour) 83 (52-121) 79 (56-127) NS 
Creatinine clearance (ml/min)  94 ± 36  91 ± 32 NS 
No. of persons with >2 renal arteries  23 24 NS 
Values are presented as means ± SD or median (interquartile range) number (% of group); BMI 
denotes body mass index, No. number, SBP systolic blood pressure, DBP diastolic blood pressure 
and HR heart rate. a measured during 133Xenon washout. 
Renal scintigraphy 
Renal scintigraphy had been performed in twelve subjects from the symmetry group and 
sixteen patients of the asymmetry group. In seven of the patients with asymmetry of 
MRBF (44%), renal scintigraphy suggested renal artery stenosis, whereas this was the 
case in only one of the subjects with symmetry of MRBF (9%). This difference was 
statistically significant (p=0.02). As judged by renal angiography, all of these subjects 
had patent renal arteries indicating that renal scintigraphy results that suggested renal 
artery stenosis must be false positive. Creatinine clearance was comparable between 
subjects with positive and negative results on scintigraphy. 
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Figure 5.1 Frequency distribution of mean renal blood flow (MRBF) ratio in 148 patients with 
essential hypertension. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kidney volume 
Adequate kidney volume measurements could be obtained in fourteen patients with 
symmetric renal blood flow and nine patients with asymmetric perfusion. Renal volume 
did not differ between left and right kidneys, either in the symmetry group (187 ml (158-
205) vs. 185 ml (166-203), NS) or in the asymmetry group (154 ml (122-179) vs. 151 ml 
(133-217), NS). When all volumes of the kidneys with the lowest flow were compared 
with those of kidneys with the highest flow, regardless of side, no differences were 
found either. This was true for patients with symmetry (184 ml (166-214) vs. 187 (153-
196), NS) as well as for those with asymmetry of MRBF (151 (128-217) vs. 154 (130-
178), NS). Although kidney volumes tended to be a bit lower in the asymmetry group as 
compared to the symmetry group, differences were not statistically significant. MRBF, 
which is expressed per 100g kidney mass, and kidney volume did not correlate (Figure 
5.2 ). 
Neurohormones 
Arterial and selective renal venous concentrations of renin, angiotensin II and 
aldosterone (Table 5.3) and veno-arterial differences of renin and angiotensin II did not 
differ between the two groups. In the asymmetry group, no differences in these 
hormones were found between the kidneys with the highest and the lowest MRBF. 
Since the left adrenal vein drains into the left renal vein, we used norepinephrine values 
from the left renal vein only when mixing with blood from the adrenal gland could 
virtually be excluded on the basis of concurrent aldosterone measurements. In each 
patient the difference between the arterial and the venous concentration of 
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norepinephrine was calculated for the kidney with the lowest flow. The same was done 
for the kidney with the highest MRBF. Although numbers were low, there tended to be a 
relation between the veno-arterial differences of norepinephrine and MRBF ratio, in 
patients with a ratio up to 2.00. This was of borderline significance when the 
norepinephrine gradient across the kidneys with the lowest MRBF was taken as 
independent variable (r=0.61, p=0.06) (Figure 5.3). 
 
Figure 5.2 Scatterplot of mean renal blood flow (MRBF) (Y-axis) and kidney volume (X-axis).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There is no correlation between left MRBF and left kidney volume (Spearman’s rho, r=-0.03, NS) 
nor between right MRBF and right kidney volume (Spearman’s rho, r=-0.14, NS); S left kidney,  
§ right kidney. 
 
 
Table 5.3 Arterial and selective renal vein concentrations of renin, angiotensin II and aldosterone 
in hypertensive subjects with symmetric and asymmetric renal blood flow. 
  Symmetry Asymmetry p 
Renin (µU/ml) Arterial  17.9 (11.8-28.4)  20.9 (11.2-38.9) NS 
(n=72 vs. n=75) Right renal vein  22.1 (14.2-34.6)  23.8 (12.8-46.1) NS 
 Left renal vein  21.7 (14.1-36.5)  24.1 (12.8-40.0) NS 
Angiotensin II (pg/ml) Arterial  11.4 (8.0-15.7)  12.9 (8.7-15.5) NS 
(n=22 vs. n=21) Right renal vein  11.2 (8.6-15.1)  11.6 (8.7-13.0) NS 
 Left renal vein  12.5 (10.1-18.7)  11.4 (9.9-14.9) NS 
Aldosterone (pg/ml) Arterial  0.38 (0.20-0.73)  0.26 (0.17-0.51) NS 
(n=14 vs. n=21) Right renal vein  0.36 (0.23-0.65)  0.22 (0.14-0.44) NS 
 Left renal vein  0.38 (0.19-0.60)  0.22 (0.16-0.27) NS 
Values are presented as median (interquartile range) 
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Figure 5.3 Scatterplot of mean renal blood flow (MRBF) ratio and the veno-arterial differences for 
norepinephrine in kidneys with the lowest MRBF. 
 
 
 
 
 
 
 
 
 
 
 
 
The correlation between the MRBF ratio and the veno-arterial difference for norepinephrine in the 
kidney with the lowest MRBF was borderline significant in subjects with MRBF ratio <2.00 
(Spearman’s rho, r=0.61, p=0.06). ● right kidney ▲ left kidney Numbers in brackets correspond to 
the actual ratio of outlying values. 
Discussion 
This study shows that substantial differences between left and right renal blood flow 
may be present in up to 51% of hypertensive patients with angiographically proven 
patent renal arteries. Inequality in perfusion between kidneys has been observed in only 
a few studies. Kioschos et al. determined selective renal blood flow by means of the dye 
dilution technique in five normotensive controls and fifteen essential hypertensives, 
including eight subjects who were suspected of having nephrosclerosis.12 In six of the 
15 essential hypertensives differences in flow between kidneys exceeded 25%, while 
asymmetry was not found in the normotensives. In a study performed by Baldwin et al. 
selective clearances of inulin and p-aminohippurate were used to investigate subjects 
who were judged to be in the early stage of essential hypertension.13 They defined 
disparity of effective renal plasma flow (ERPF) as being abnormal when it exceeded the 
90th percentile of differences between two kidneys in subjects with normotension and 
found this to be present in 19 out of 36 patients. Interestingly, in 16 of these patients this 
was accompanied by a concordant disparity of the glomerular filtration rate (GFR). In a 
more recent study, Van Jaarsveld et al. evaluated in a large group of hypertensive 
patients Technetium-99 labeled diethylenetriamine pentaacetic acid (99mTc-DTPA) 
scintigraphy.14 They noticed that, without captopril challenge, the single kidney fractional 
uptake was statistically significantly lower on the left side than on the right side (46% vs. 
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54%). Unfortunately, dye dilution and clearance techniques generate absolute flow 
values per kidney, whereas scintigraphy results are presented as a percentage 
contribution of each kidney. So, differences in kidney volume may have confounded 
these data. On the other hand, the 133Xenon-washout technique, which we applied in 
the present study, measures flow per unit of kidney mass. Therefore, our data on 
differences in flow between the left and right kidney cannot be explained by differences 
in kidney mass. To strengthen this point we have determined kidney volumes in a 
subset of our patients who underwent CT angiography and these data do not point to 
any association between kidney volume and asymmetry of renal blood flow in our study 
population either. 
 
From sequential renal blood flow measurements in the same kidney in patients with 
essential hypertension, Hollenberg et al.15 observed differences in flow which were 
comparable to those between the two kidneys as found by Baldwin et al.13 Compared to 
normotensive controls, renal blood flow in patients with essential hypertension exhibited 
a 2.2 fold greater variability, which the authors contributed to sinusoid-like oscillations in 
renal blood flow with a similar cycle length (about 40 seconds) but increased maximal 
amplitude.15,16 It can be concluded from their experiments that the total variability of 
blood flow in each kidney will randomly result in significant flow differences between 
both kidneys. Although this phenomenon may have contributed to our results, in our 
opinion it is not sufficient to explain our observations. After all, we measured 133Xenon 
washout for three minutes, which is almost five times the duration of the oscillatory cycle 
length, thereby outweighing the effect of oscillations by far.  
 
Inequality of renal blood flow between the kidneys, therefore, is likely to originate from 
structural or functional differences, or both. The degree of structural abnormalities at the 
level of interlobar and arcuate arteries has been shown to correlate with renal blood flow 
and renal vein renin levels.17,18 Regarding the symmetry of peripheral abnormalities on 
renal angiography, literature is inconclusive. Arlart et al.18 found approximately 
symmetric peripheral involvement, whereas Caralps et al. demonstrated asymmetric 
alterations of the interlobar and arcuate arteries in eleven out of 25 patients.19 
Interestingly, the latter investigators reported in ten out of the eleven asymmetry cases 
that the left kidney was more affected than the right one. The smallest renal vessels 
have been studied in two large histopathologic studies using bilateral kidney biopsies of 
hypertensive subjects. The severity of arteriosclerotic changes differed between the 
kidneys in 25 to 39% of all cases.20,21 However, these numbers are difficult to interpret 
in the light of inter- and intraobserver disagreement rates of 13% and 20% 
respectively.21 Additionally, it has been observed that there is also intrarenal 
heterogeneity of arteriosclerotic changes in the renal cortex.21,22 Apart from structural 
abnormalities, asymmetry in renal perfusion could also be caused by functional 
differences between kidneys. However, in our population, renin levels did not differ 
between subjects with symmetry and those with asymmetry. Although not identical to 
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norepinephrine release rates23 and available only in a small subgroup, veno-arterial 
differences of norepinephrine were not symmetric in our study and tended to be the 
highest in patients with more pronounced grades of asymmetry. In patients with 
differences in MRBF exceeding 200% this relation is absent, which may indicate that 
with severe asymmetry different pathophysiological processes are involved. 
Interestingly, recent data suggest that in isolated renal arteries from WKY rats the 
vasoconstrictor responses to electric field stimulation are enhanced on the left side, 
which may be explained by a more dense sympathetic nerve innervation of the left 
kidney.24 
 
Whatever the nature of the (patho)physiologic process(es) leading to asymmetry of 
renal blood flow, our study shows that the asymmetric phenotype coincides, at least in 
the subgroup that we were able to study, with an increased rate of false-positive results 
on renal scintigraphy. This provides evidence that the presence or absence of 
asymmetry is a consistent characteristic, which may interfere with the accuracy of 
diagnostic tests that depend on renal blood flow. 
 
An obvious limitation of our study is that we measured MRBF only once in every kidney 
on one occasion. Therefore, we do not know whether asymmetry is really a consistent 
trait in a particular person. Secondly, our data were obtained in a selected population of 
patients who were suspected of renal vascular disease. To what extent our data can be 
extrapolated to the entire hypertensive population remains elusive. Thirdly, we perform 
blood flow studies in a fixed order, first left then right. One may argue that our findings 
are biased by an order effect, especially because we found asymmetry to occur more 
often at the expense of the left kidney. However, in 31 of the 75 subjects (41%) with an 
asymmetric flow pattern, right RBF was lower than left RBF. In case of a strong and 
predominant order effect, we would have expected this fraction to be much less. A 
reason for an order effect may be that the stress related to the measurements would 
lower the first measurement. However, the fact that heart rate and blood pressure 
remained constant during the measurements, indicates that the level of arousal did not 
change during the wash-out studies. Moreover, we did not detect systematic differences 
between repeated measurements in the same kidney in reproducibility studies. In this 
context we also like to stress that all measurements are completed within ten minutes, 
thereby reducing time-dependent variation in renal blood flow as found by Persson et al. 
in conscious dogs.25 Finally, our data leave unanswered the question whether 
asymmetry is an inborn phenomenon or a consequence of (longstanding) hypertension.  
Perspectives 
Over 40 years ago, the first reports regarding asymmetric renal perfusion were 
published. However, the small study sizes and methodology hampered implement of 
their findings. We have revisited this subject, and have demonstrated considerable left-
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to-right differences in renal blood flow in a substantial number of subjects in a well-
defined group of patients with severe hypertension. Clearly, more studies are necessary 
to define underlying mechanism(s) and the exact clinical importance of this 
characteristic. For now, we think our results underscore the importance of studying the 
function of both kidneys separately, since it cannot be assumed a priori that they are 
functionally equal. 
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Abstract 
Marked asymmetry of renal blood flow and renin activation are the corner stones of 
pathophysiology in experimental unilateral renovascular hypertension. In humans, the 
interrelationships between atherosclerotic unilateral renal artery stenosis (ARAS), renal blood flow 
and renin actitivity remain to be elucidated, especially since renal patency restoration is not always 
beneficial. Mean renal blood flow (MRBF; 133Xenon washout technique), renin activation and 
creatinine extraction of both kidneys were determined in hypertensive patients with (n=59) and 
without (n=261) unilateral ARAS. High(er) grade(s) (of) ARAS (>50%) coincided with an increased 
volume-normalized difference (“asymmetry”) in MRBF between the stenosed and the contralateral 
kidneys. Still, in half of the patients, flow through a kidney with ARAS was similar or even higher. 
Patients with an asymmetric pattern had a higher renin activity (both high grade and low grade 
ARAS) and lower extraction of creatinine (only in high grade ARAS) in a kidney with ARAS. Up to 
one year after revascularisation, patients with a symmetric perfusion had a lower pulse pressure 
than patients with an asymmetric perfusion, whereas mean arterial pressure was similar. 
Asymmetric perfusion, rather than the stenosis per se, may be associated with adverse functional 
consequences. 
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Introduction 
In experimental models, renal artery stenosis does not decrease blood flow through the 
affected kidney until the lumen is reduced by about 75%.1,2 The fall in blood flow is 
associated with increased renin secretion, which, via angiotensin II mediated efferent 
vasoconstriction, acts to preserve glomerular filtration rate in the affected kidney. Blood 
flow through the contralateral kidney rises which leads to a marked perfusion 
asymmetry between the kidneys.3 However, in patients, in whom renal artery stenosis 
develops more gradually over time, the picture is more complicated. First of all, subtle 
changes in renal blood flow may already become apparent when the lumen is reduced 
by as little as 30%.4 Also, the amount of renin activation does not discriminate well 
between patients with and without renal artery stenosis.5 Finally, as we showed 
previously, also about half of the patients with essential hypertension and patent renal 
arteries have a significant difference in blood flow through the left and the right kidney.6 
Thus, the relationship between the degree of luminal reduction of the renal artery, renal 
blood flow and individual kidney function may be less straightforward than is generally 
thought. This prompted us to determine the prevalence of asymmetric renal perfusion in 
patients with unilateral renal artery stenosis, and to compare renin activation and 
individual kidney function in those with and without asymmetric perfusion. Further, the 
effect of restoration of renal patency on the blood pressure was compared between 
these two groups. 
Materials and methods 
Study protocol 
Since February 1994, all patients who are referred to our clinic for evaluation of their 
hypertension (i.e. systolic blood pressure above 140 mmHg and/or diastolic blood 
pressure above 90 mmHg on at least three occasions) are subjected to a standard 
diagnostic protocol. This includes renal angiography with selective renal blood flow 
measurements and arterial and renal venous blood sampling when patients meet one or 
more of the following criteria: hypertension despite two or more antihypertensive drugs, 
accelerated hypertension, documented atherosclerotic vascular disease in two or more 
vascular beds, presence of an abdominal bruit or an unexplained impairment of renal 
function in response to antihypertensive treatment.  
 
For reasons of standardisation, all antihypertensive medication is discontinued for three 
weeks and patients are requested to use a sodium-restricted diet (55 mmol/24h) during 
the week preceding the study. After an overnight fast, the aorta and both renal veins are 
cannulated via the femoral route and blood samples are drawn simultaneously from the 
aorta and renal veins for measurement of active plasma renin concentration (APRC) 
and creatinine. Subsequently, we measure selective mean renal blood flow (MRBF) by 
means of the 133Xenon washout technique7,8 as described previously.9,10 We always 
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commence 133Xenon washout studies in the left kidney and the whole Xenon wash-out 
procedure for both kidneys is completed within approximately ten minutes. Blood 
pressure and heart rate are monitored during the MRBF measurements and no contrast 
agent is administered before the flow studies have been completed. Thereafter, intra-
arterial renal angiography is performed with a commercially available digital subtraction 
system (Integris 5000; Philips Medical Systems; Best, The Netherlands).  
 
The 133Xenon washout curves are analysed off-line using a two-phase exponential 
model, after subtraction of background radiation.7,8 (GraphPad Software, Inc., San 
Diego, CA). The first (fast) component is thought to represent cortical renal blood flow, 
whereas the other component probably cannot be attributed to specific parts.8,9 In our 
hands, the 95th percentile of differences between two repeated flow measurements in 
the same kidney is 25% (mean variability of two measurements plus two times the 
standard deviation), without systematic left-right differences between first and second 
measurements.  
Angiographic films 
Two experienced readers evaluated all angiographic films. In case of abnormalities, 
they reported on the site and nature of the aberration on standardized forms. In the case 
of atherosclerotic disease, maximum stenosis was measured as:  
 
(1-(narrowest diameter/diameter of the normal distal main renal artery)) x 100%.  
 
If the two estimates of the degree of stenosis differed by more than 10% (of the highest 
assessment), a third opinion was decisive.  
Clinical follow-up 
Of all patients who underwent angioplasty and/or stenting or surgical renal artery 
reconstruction, blood pressure values, number of antihypertensive drugs and serum 
creatinine concentrations were derived from their medical records (three months and 
one year after the intervention). If patients were not treated at our clinic in that period, 
we contacted their current physicians. Benefit of revascularisation was defined as a 
decrease of systolic and/or diastolic blood pressure by at least 15 mmHg while using the 
same or less antihypertensive drugs. All other outcomes were classified as failure.  
All patients gave written informed consent and the Maastricht University Hospital 
Medical Ethics Committee approved the study. 
Assay methods 
Active plasma renin concentration (APRC) was measured using a two-site 
immunoradiometric assay method.11 Standard methods were used for the measurement 
of creatinine. 
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Calculations and definitions 
Creatinine clearance was estimated by the Cockcroft formula.12 We estimated the 
extraction ratio of creatinine per kidney as the difference between the arterial and 
venous concentration of creatinine divided by the arterial concentration and the APRC 
ratio as the difference between the venous and arterial concentration of APRC divided 
by the arterial concentration. 
 
For each patient, we calculated the absolute asymmetry index for renal blood flow as:  
 
| left MRBF – right MRBF | 
(MRBF left + MRBF right)/2 
 
In the absence of asymmetry in MRBF and renal artery stenosis, we expected a 
maximum difference between the left and the right kidney MRBF of approximately 25% 
(mean variability of two measurements in the same kidney plus two times the standard 
deviation), which is equal to a value of 0.22 of the asymmetry index. Therefore, we 
defined symmetry of MRBF as an asymmetry index <0.22 and asymmetry as an index 
>0.22. In previous work, we calculated the asymmetry index in a slightly different way 
namely as flow in the kidney with the highest MRBF divided by that in the kidney with 
the lowest MRBF.6 The main advantage of the present asymmetry index is the linear 
scale, which enables its use in more advanced statistical models without the otherwise 
inevitable need for transformation. The cut-off value of 0.22 of the new index is equal to 
the previously applied 1.25 of the MRBF ratio.  
 
Experimental data suggest that renal blood flow is not affected until the lumen is 
obliterated by at least 75%.1, 2 This is comparable to a stenosis of approximately 50% as 
measured by 2-dimensional digital subtraction angiography.13 Therefore, in the 
analyses, patients were divided in three groups: no abnormalities (ARAS-), renal artery 
stenosis <50% (low grade ARAS) and renal artery stenosis >50% (high grade ARAS). 
Statistical analysis 
Differences between the groups were analysed using either unpaired parametric t-tests 
or non-parametric tests or Pearson Chi-square tests. We explored the relationship 
between the absolute asymmetry index and factors with potential effect on renal blood 
flow further by forward stepwise linear regression analysis (with p to enter set at 0.05 
and p for removal at 0.1). We considered: age, sex, body mass index, pulse pressure, 
mean arterial pressure, heart rate, serum creatinine, %-stenosis and APRC ratios. 
Transformation of variables was applied if necessary. We used SPSS 11.5 for all 
statistical analysis. A p-value of <0.05 was considered statistically significant. Data with 
a normal distribution are presented as means ± SD, otherwise medians and interquartile 
ranges are given. 
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Results 
Successful measurements of MRBF on both sides were available in 381 patients: 261 
without abnormalities and 119 with renal artery stenosis. The latter group consisted of 
59 patients with atherosclerotic unilateral stenosis (median percentage luminal reduction 
44% (25-74)), 30 patients with atherosclerotic bilateral stenosis (median percentage 
luminal reduction 59% (40-68)), 28 patients with fibromuscular dysplasia (FMD: 
18 unilateral, 10 bilateral) and two patients with FMD on one side and atherosclerosis 
on the other. The analyses presented in this paper will be confined to the group of 
patients without abnormalities on renal angiography (ARAS-) and the group with 
unilateral atherosclerotic renal artery stenosis (ARAS+). Data of patients with FMD and 
bilateral atherosclerotic renal artery stenosis will be presented only for the comparison 
of the prevalence of asymmetry. 
Patient characteristics 
Patient characteristics are presented in Table 6.1. As expected, patients with ARAS+ 
were older, more often male and hypercholesterolemic. In addition they had higher 
pulse pressure, lower estimated creatinine clearance and more often manifestations of 
extra-renal atherosclerosis.  
 
Table 6.1 Patient characteristics 
 ARAS- Unilateral ARAS+ p 
 n=261 n=59  
Age (years) 50±13 62±9 <0.0001 
Sex (male/female) 144/117 42/17 0.03 
Body mass index (kg/m2) 28±5 27±4 0.34 
Smoking (%) 59 70 0.10 
Office systolic blood pressure (mmHg) 169±29 175±25 0.07 
Office diastolic blood pressure (mmHg) 100±16 92±13 <0.0001 
Office pulse pressure (mmHg) 69±22 82±23 <0.0001 
Office mean arterial pressure (mmHg) 123±18 119±14 0.18 
Creatinine clearance (ml/min) 91±39 69±24 <0.0001 
Diabetes mellitus (%) 11 18 0.14 
Hypercholesterolemia (%) 27 54 <0.0001 
Extra-renal atherosclerosis (%) 26 59 <0.0001 
 
Within the diagnostic groups, patients with symmetry (SYM) and asymmetry (ASYM) of 
flow did not differ substantially regarding patient characteristics. ASYM ARAS- subjects 
suffered somewhat less often from hypercholesterolemia (19% vs. 33%, p=0.03) and 
extra-renal atherosclerosis (18% vs. 33%, p=0.01) than the SYM ARAS-. ASYM ARAS+ 
had, on average, a higher body mass index than SYM ARAS+ (28 (27-32) vs. 25 (23-
28), p=0.005). During the flow measurements blood pressure remained constant in all 
patient groups.  
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Prevalence of Asymmetry 
The prevalence of asymmetry was almost similar in the group without abnormalities 
(45%) and in the group with unilateral renal artery stenosis (50%). Subjects with FMD 
had less often apparent differences between the kidneys regarding flow (unilateral FMD 
31%, bilateral FMD 39%) whereas subjects with bilateral atherosclerotic renal artery 
stenosis had the highest prevalence of asymmetry (62%) 
Grade of luminal reduction and asymmetry 
A greater degree of luminal reduction coincided with a larger difference in MRBF 
between the kidney with the stenotic renal artery and the non-stenotic one. Yet, kidneys 
with unilateral ARAS did not always have a lower MRBF than the non-stenotic kidney. In 
fact, in half of the patients with stenosis >50%, blood flow per unit mass of tissue 
through the kidney on the side of the renal artery stenosis was similar (43%) to or even 
higher (7%) than that through the non-stenotic kidney. (Figure 6.1) 
 
Figure 6.1 Asymmetry index in relation to lumen reduction (%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
¡ MRBF of the kidney with unilateral ARAS < MRBF of the contralateral kidney; { MRBF of the 
kidney with unilateral ARAS > MRBF of the contralateral kidney. This figure depicts the grade of 
stenosis versus the asymmetry index.  
Split renal function 
Figure 6.2 presents MRBF, APRC ratio and creatinine ratio per kidney for the three 
diagnosis groups, ARAS- is depicted for reasons of comparison only. 
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Figure 6.2 Split renal function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are presented as means and interquartile range. a,b, c and d denote p-value <0.05 and e, f and 
g denote p-value 0.05-0.10 for comparisons between (or within) groups. This figure shows MRBF 
(upper panel), APRC (middle panel) and creatinine ratio (lower panel) through kidneys with 
unilateral ARAS (    ) and the non-stenotic kidney (   ) (or through left (   ) and right (   ) kidneys in 
ARAS-).  
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High grade unilateral ARAS 
ASYM had a lower MRBF through the stenotic kidney. APRC values differed to a great 
extent between patients. The APRC tended to be higher in the stenotic kidneys of 
ASYM as compared to SYM, the difference was, however, not statistically significant 
(p=0.09). The extraction of creatinine was significantly lower in the stenotic kidneys of 
ASYM as compared to SYM. When the two kidneys of ASYM were compared, the 
stenotic kidney received less flow (p=0.001), had a higher APRC ratio (p=0.06) and 
extracted less creatinine (p=0.03) than the non-stenotic kidney.  
Low grade unilateral ARAS 
Patients with low grade stenosis showed an intermediate pattern: patients with ASYM 
seemed, on average, to have slightly lower flow through the stenotic kidney and higher 
flow to non-stenotic kidney compared to SYM, but this was not statistically significant. 
The APRC ratio in the non-stenotic kidney was higher in ASYM (p=0.09), but the 
extraction of creatinine was similar.  
Multivariable analysis 
In the group of patients without renal artery stenosis, only mean arterial pressure was 
weakly related to the asymmetry index. (R2=0.04, p=0.01). In the group of patients with 
renal artery stenosis, 28% of the variance of the asymmetry index was explained by 
three variables: body mass index, grade of stenosis (%), the APRC ratio of the kidney 
contralateral to the stenosis (p<0.0001). 
Clinical consequences of asymmetric perfusion 
Twenty-three out of the 28 patients with a high grade stenosis underwent renal 
revascularisation (two surgical reconstruction, 21 percutaneous transluminal renal 
angioplasty (with the insertion of a stent in 14). Judged by (immediate) post-
interventional angiography films, PTRA was technically successful in all cases. Four 
patients who did not undergo PTRA were treated with medication only; in one of these 
because of occlusion of the vessel, in one because the non-stenotic kidney produced 
APRC whereas APRC production was depressed in the stenotic kidney, in one patient 
there was a good clinical response to medication and in one patient angiographic 
abnormalities had been judged to be not severe enough to impede blood flow at the 
time of the angiography (whereas the panel of radiologists of this study judged 
differently). One other patient died before the scheduled date of the PTRA. During 
follow-up period, one patient died two days after surgical revascularisation and of one 
patient no blood pressure measurements were available during a visit to our the 
outpatient clinic while using medication. Analysis of the clinical outcome after three 
months, was, therefore, performed on data of 21 patients. Four patients underwent 
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intervention less than a year ago, therefore the outcome after one year was evaluated in 
17 patients. Figure 6.3 shows that blood pressure had decreased after the intervention.  
 
Figure 6.3 Change of blood pressure after three months and one year after revascularisation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This figure shows blood pressure response (mean arterial pressure and pulse pressure) three 
months (n=21) and one year (n=17) after revascularisation in patients with symmetry (      ) and 
asymmetry (     ). Reduction of mean arterial pressure was similar between these two groups, 
however, pulse pressure only fell in patients with symmetric perfusion. 
 
 
SYM and ASYM had about comparable reduction of the mean arterial pressure at three 
months (16 (-2–28) vs. 8 (-3–13) mmHg, p=0.12) and at twelve months (25 (2-36) vs. 11 
(0-25) mmHg, p=0.34). However, in SYM the reduction in pulse pressure tended to be 
more pronounced than in ASYM both at three months (16 (4-27) vs. -1 (-10–15) mmHg, 
p=0.07) and at twelve months (20 (6-40) vs. 3 (-7–19), p=0.06) (Figure 6.3). The two 
groups did not differ with respect to the number of prescribed antihypertensive drugs. 
(SYM vs. ASYM: at baseline 2.0 (1.8-3.0) vs. 2.0 (2.0-2.0) drugs, at three months 2.0 
(1.0-3.0) vs. 2.0 (2.0-3.0) drugs and at one year 2.0 (1.3-3.0) vs. 2.0 (2.0-3.0) drugs)). 
Possibly because of low numbers, none of the differences between responders and 
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non-responders reached statistical significance threshold. Patients whose outcome was 
classified as failure were characterised by a higher asymmetry index ((0.53 (0.16-0.75) 
vs. 0.16 (0.07-0.46), p=0.09) and a lower MRBF on the stenotic side (111 (63-162) vs. 
154 (107-260) ml/min/100g, p=0.18) than responders. Non-stenotic MRBF was however 
similar (195 (133-222) vs. 194 (125-242) ml/min/100g, p=0.83). APRC ratios of non-
responders and responders were 0.27 (0.08-1.23) and 0.12 (-0.04-0.63) (p=0.23) in the 
stenotic kidney and 0.07 (-0.01-0.14) and 0.03 (-0.13-0.12) (p=0.32) in the non-stenotic 
kidney. 
Discussion 
The present study focused on the comparison of the two kidneys in the presence of 
unilateral atherosclerotic renal artery stenosis and hypertension. Higher grades of 
luminal reduction coincided with an increased difference in MRBF between the stenotic 
and the non-stenotic kidney. However, in half of the patients with high grade stenosis, 
flow through the kidneys was similar or even higher in the kidney with renal artery 
stenosis than in the contralateral one. Since we measured flow per 100 grams of kidney 
mass, it may very well be that, in absolute terms, patients with a symmetric flow have a 
clear-cut difference in absolute RBF between both kidneys when these have different 
volumes. Differences in flow in this study relate to actual differences of flow per unit of 
functional mass. Whether a reduction in flow is focal or more uniformly distributed 
throughout the kidney, cannot be determined from our data.  
 
Most human research has focused less on differences between the stenotic and the 
contralateral kidney per patient than on average flow rates through the stenotic and 
contralateral kidneys in groups of patients with renovascular disease. For example, 
Kimura et al.14 found that the average RBF and GFR were lower in the unilaterally 
stenotic kidney and higher in the contralateral kidney compared to kidneys of patients 
without renal artery stenosis. Further, they calculated that the contralateral kidney must 
suffer from glomerular hypertension and hyperfiltration. In our study, perfusion rate 
through a kidney supplied by an artery with a high grade stenosis, was lower than the 
average value of the group of patients without renal artery stenosis. However, blood 
flow through the other kidney was similar to the average value of subjects without 
stenosis. This kidney extracted higher amounts of creatinine per 100 g of kidney mass 
than the stenotic one. Renal APRC ratio was higher in the stenotic than in the 
contralateral kidney (of borderline statistical significance). Hence, at first glance, our 
results are completely consistent with the common view on unilateral flow reduction in 
renal artery stenosis.14 At closer examination, however, this pattern was not seen in the 
half of the patients displaying symmetry of flow. Reasons for this do not become clear 
from our data since patients with and without symmetry were remarkable similar with 
respect to patient characteristics. Multivariable analysis revealed only the degree of 
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stenosis, renin activity and BMI as independent predictors of the grade of asymmetry. 
Considering the central role of the renin-angiotensin system in the (initial) elevation of 
blood pressure in animals with lumen artery restriction, we hypothesise that the 
presence of (a)symmetry may be reflecting whether a renal artery stenosis is the origin 
of hypertension and renal dysfunction in a patient or just an innocent bystander. As 
previously reported, in the group of patients without any renal artery abnormalities, 45% 
presented with clear-cut asymmetry. This was, however, unrelated to renin activity, 
possibly suggesting a different etiology.6 Strikingly, patients with unilateral renal artery 
stenosis caused by fibromuscular dysplasia had the lowest prevalence of asymmetric 
perfusion (31%). Unfortunately, the number of patients with FMD was too small to allow 
any meaningful statistical testing. 
 
Also, few experimental studies have investigated differences between both kidneys per 
animal. Sigmon et al.15 studied differences in RBF between the kidneys of 2K,1C rats. 
They intended to induce unilateral renal artery stenosis of less than 80% by clipping the 
blood supply to one of the two kidneys of rats in a series of experiments. They used 
clips with different internal diameters. Due to the impossibility to accurately measure 
luminal reduction in rats, they calculated the weight-corrected ratio of the non-clipped to 
the clipped RBF as a functional index. They defined a ratio <1.25 as mild stenosis and a 
ratio >1.30 as moderate stenosis. Both groups were hypertensive and had similar blood 
pressure, cardiac output and total peripheral resistance. Absolute flow through the 
clipped kidney and mass was always reduced four weeks after clipping. However, 
moderate stenotic rats had a 2.6 fold higher plasma renin activity fifteen minutes after 
endothelial nitric oxide synthase inhibition with L-NAME than mildly stenotic ones. They 
assumed that their functional classification paralleled anatomical luminal obstruction, 
despite the absence of any correlation between clip size and blood pressure or degree 
of stenosis. We found that even in patients with stenosis >50%, only the half showed a 
lower blood flow through the stenotic kidney than through the contralateral one. So, in 
the light of our findings, it is very tempting to interpret the data of Sigmon et al. on the 
absence of a clear-cut relation between clip size (and thus degree of lumen obstruction) 
and differences between the kidneys in renal blood flow, as, indeed, circumstantial 
evidence that the phenomenon we observed is also apparent in experimentally induced 
2K1C hypertension. Interestingly, in more recent work they studied 2K1C hypertension 
in thirteen weeks old rats. Only 50% of the clipped rats survived until thirteen weeks and 
none of them presented with asymmetric perfusion pattern.16 They hypothesized that 
adaptation to a certain “normal” flow value, might be pivotal for rats in order to survive.  
 
The results of renal revascularisation are disappointing in many patients with 
atherosclerotic renal artery stenosis. This has been the incentive for the search for 
predictors of a beneficial outcome. In this respect, the degree of renin activation and 
renal hemodynamics have received a lot of attention. Initially, a profound role for the 
determination of renin activity was suggested,17 but later studies have tempered this 
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enthusiasm.18,19 In our study, (high) renin activity was a predictor of asymmetry. So, 
since asymmetric patients responded worse to revascularisation, if anything, renin 
activity was associated with worse outcome. This confirms findings from the group of 
Radermacher et al. who reported that an increased plasma renin activity was associated 
with a worsening of renal function after revascularisation, although this result did not 
sustain in multivariable analysis.20 For the renal hemodynamic variables, the 
discriminative abilities of flow through the stenotic kidney and the contralateral kidney 
have been studied. Volume-normalized blood flow through stenosed kidneys did not 
differ between responders and non-responders,21 whereas (absolute) blood flow through 
the kidney contralateral to unilateral stenosis was on average found to be lower in 
responders, although with considerable overlap between categories.22 However, the 
interpretation of the latter study is complicated. In that study, only patients with either an 
asymmetric scintigram or an (unilateral) abnormal excretatory urogram were subjected 
to intra-arterial angiography. Further, in 20% of their patients surgical revascularisation 
was performed because of segmental renal artery stenosis (as diagnosed by functional 
studies) in the absence of (main) renal artery stenosis on intra-arterial angiography. 
Therefore, selection bias may have been present. In the present study, responders and 
non-responders did differ with respect to flow through the kidney supplied by an artery 
with (high grade) stenosis, however this result was not statistically significant. 
Considering the great interindividual variability of renal blood flow between patients with 
hypertension,23 the low predictive value does not seem very surprising. It has been 
known for a long time that an unilateral decrease in perfusion pressure lead to changes 
in hemodynamics and volume not only in the ipsilateral but also in the contralateral 
kidney. Furthermore, it has been suggested that the contralateral kidney is exposed to 
systemic hypertension, while the kidney on the stenotic side is “protected” by the 
stenosis.24,25 Whether the kidneys are adapting to these changes may be reflected by 
differences with respect to volume-corrected flow between the kidneys. We found that 
asymmetry of renal blood flow may have adverse functional consequences since blood 
pressure responses to revascularisation seemed to be less marked in patients with 
asymmetry than in patients with a symmetric perfusion pattern. Findings from other 
groups studying indices of both kidneys, lend some support to this hypothesis. Studies 
with captopril renography found that severe asymmetry regarding relative clearance 
values by the kidneys was more common in non-responders than in responders,18 and if 
both kidneys display a (very) high intra-renal resistance, the change of a favourable 
outcome after renal revascularisation is low.20  
Conclusion 
In patients with renal artery stenosis, asymmetry of renal blood flow was not as 
consistently present as commonly assumed and neither necessarily at the expense of 
the stenotic kidney. Asymmetry was associated with functional consequences: higher 
renin activation, lower extraction of creatinine and a less favorable outcome after 
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revascularisation. Asymmetric perfusion, rather than the stenosis per se, may be 
associated with adverse functional consequences. Further studies into mechanisms of 
asymmetry of renal blood flow may provide new insights for the role of renal 
revascularisation in atherosclerotic renal artery stenosis. 
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Abstract 
The goals of restoration of renal artery patency are usually two-fold: to improve blood pressure 
control and to stabilize (or even improve) renal function. The effect on renal function is, however, 
largely unknown since results of studies are conflicting, possibly as a result of small study sizes 
and differences in study design and patient selection. The large number of studies that have been 
published raises the opportunity to study by meta-anlysis the effect of intervention on renal function 
in a large congregate of patients. A comprehensive search of MEDLINE and EMBASE was 
undertaken to identify all studies that evaluated the effect of renal patency restoration on serum 
creatinine in patients with hypertension and renal artery stenosis with a clinical follow-up of at least 
three months. Although average change of creatinine after intervention differed greatly between the 
individual studies, serum creatinine concentration after intervention fell by 5 µmol//l (p=0.04). Renal 
patency restoration in patients with atherosclerotic renal artery stenosis and hypertension may lead 
to a modest improvement of renal function. Whether this effect has clinical relevance is uncertain. 
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Introduction 
Atherosclerotic renal artery stenosis (ARAS) is associated with hypertension and renal 
dysfunction and is a progressive over time. In a study examining the natural history of 
ARAS by duplex scanning, 49% of arteries with high grade ARAS (>60% stenosis) 
showed progressive reduction of the arterial lumen and 56% of the arteries with low 
grade ARAS (<60% stenosis) progressed to the category of high grade stenosis within 
three years despite of the use of antihypertensive medication.1 The goals of restoration 
of renal artery patency, therefore, are usually two-fold: to improve blood pressure 
control and to stabilize (or even improve) renal function. Since the introduction of PTRA, 
a large number of (mainly observational) studies has been published on the clinical 
outcome after various forms of intervention. The results of these studies are, however, 
conflicting, possibly as a result of small study sizes and differences in study design and 
patient selection. Nevertheless, the availability of these studies raises the opportunity to 
asses by meta-analysis the effect of intervention on renal function in a large congregate 
of patients in a longer time frame. Here we report on the results of such a meta-
analysis. Further this meta-analysis aimed to explore which factors determined 
differences in outcome between studies. 
Materials and methods 
Search strategy 
A comprehensive search of MEDLINE and EMBASE was performed using the following 
terms: (hypertension, renovascular OR reno* hypertension* OR renal artery obstruction 
OR renal artery stenosis OR atherosclerotic renal disease OR atherosclerotic 
renovascular disease) AND (PTRA OR percutaneous transluminal renal angioplasty OR 
angioplasty, balloon OR stent* OR vascular surgical procedure OR surgical 
revascularisation OR revascularisation OR revascularisation). No starting date was 
specified and the search was updated until February 1th 2005. Only studies published in 
English, German, French or Dutch were selected. Abstracts of the selected manuscripts 
were screened for inclusion- and exclusion criteria. If relevant, or if the abstract did not 
contain sufficient information to decide about the relevance, the full text of the article 
was retrieved. Further, the reference lists of the obtained articles were screened for 
potentially eligible studies. 
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Study selection 
Studies were included in the meta-analysis when they met the following criteria: 
1. The intervention consisted of either surgical revascularisation or percutaneous 
transluminal renal angioplasty with/without the insertion of a stent, or a combination 
of these. 
2. The inclusion of patients (whether prospective or retrospective) was consecutive 
and thus the study population did not represent a subgroup of any kind.  
3. Absolute creatinine concentrations or calculated creatinine clearances and the 
appropriate standard deviation values measured before and after intervention were 
given, or these values could be derived from the data or obtained on written request 
to the corresponding author. 
4. Follow-up after the intervention was at least three months. 
5. At least 95% of the patients was hypertensive (blood pressure >140/90 or the use 
of antihypertensive medication) before intervention. 
 
Studies were excluded when: 
1. In >5% of the cases, renal artery stenosis was  
− detected incidentally during angiography for other reasons than suspicion of 
renovascular hypertension, and/or 
− of non-atheromatous etiology, and/or  
− caused by re-stenosis of previously successfully treated lesion(s), and/or  
− located in a transplant kidney 
2. The report consisted of less than 20 patients who completed follow-up of three 
months 
3. A more recent study of the same researcher or research group was available, 
unless it was beyond doubt that a different patient sample had been used.  
Data extraction 
Relevant data from included studies were abstracted by two of us by use of a 
standardized form. If available, data were abstracted regarding patient source, (primary) 
indication for intervention, lesion characteristics, the applied intervention(s), renal 
function (creatinine or calculated creatinine clearance (with appropriate standard 
deviation(SD))), and potential confounders (age, gender, presence of diabetes mellitus, 
blood pressure and body weight). Discrepancies in the extracted data were resolved by 
the two authors examining the articles together. 
Assessment of study quality 
The quality of the studies was evaluated by use of the checklist by Downs and Black 
that allows the assessment of both randomised and non-randomised studies.2 This 
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score assesses reporting, external validity, bias, confounding and power. With respect 
to power, this score needs to be customized. Since it would take 170 patients in order to 
detect a difference of serum creatinine >5 µmol/l, (assuming a SD of 20, α=0.05 and 
1-β=0.90) , 0 points were given when the number of patients at follow-up was less than 
169, 1 point when between 170 and 339, 2 points between 340 and 509, 3 points 
between 510 and 679, 4 points between 680 and 849 and 5 points when more than 850 
patients were included. We omitted items that were not applicable to any of the studies 
(numbers 1, 10, 14, 18, 21, 22 and 25). Quality was assessed by two of us and in case 
of disagreement discussed until consensus was reached. 
Data synthesis and analysis 
For each study, the difference (Diff) in average creatinine at baseline (C0) and average 
creatinine at twelve months after intervention (C1) was calculated as: Diff=C0-C1. If no 
measurement at twelve months was provided we used, in order of preference, the 
measurement after six, three or 24 months. The SE of Diff was calculated as:  
 
2*pooled variance(C0,C1)*(1-r) 
 
(SEDiff)2 = n 
 
Where n is the number of patients, (when number of patients at baseline did not equal 
the number of patients at follow-up, the average of that was used) and with r the 
correlation between C0 and C1. Since this correlation is generally not reported, this was 
estimated to approximate the intra-individual day-to-day variability3, and a value of 0.94,5 
was imputed for all studies. In two studies6,7 SE in stead of SD was reported and in 
these cases, SD was calculated as SE * √n. In two studies in which standard deviations 
were not provided, we imputed the SD of another (included) study that did provide SD 
and was most comparable with respect to number of participants and methodology.8,9 It 
should be noted that imputation of SD affects the weight of the study but not the effect 
measure.  
 
The overall effect of intervention on renal function was calculated as the weighted 
average of the Diff of all studies by the inverse variance weight method. The presence 
of heterogeneity between studies was assessed by the Q statistic (p-value for 
significance: 0.1) and the forest plot. In case of heterogeneity between studies we 
applied a random effects model, otherwise a fixed effect model was used. The following 
potential sources of heterogeneity were considered upfront: publication year, type of 
intervention, lesion characteristics (unilateral vs. bilateral, ostial vs. non-ostial disease), 
certain patient characteristics (age, blood pressure, presence of diabetes mellitus), 
% lost to follow up). The amount of missing data prevented the sensible application of a 
mixed effect model with potential sources of heterogeneity as covariables.10 Therefore, 
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heterogeneity was further explored through stratified analysis. Analyses were performed 
with StataSE 8.0. 
Results 
We identified 2768 published studies and 190 among these were potentially eligible 
after screening the abstract and the full text of these articles was obtained. Of twelve 
papers, we could not retrieve the full text. We approached the corresponding authors of 
21 manuscripts for additional information, of whom nine responded and six were able to 
supply the requested data. The present analysis includes 28 studies. Table 7.1 provides 
reasons for exclusion of studies. A complete reference list of the excluded papers can 
be obtained from the authors. The most frequent cause for rejection of a patients series 
was that the effect of intervention on renal function was not reported in sufficient detail 
to allow pooling for this analysis. Usually, the more recent studies described the renal 
outcome, but expressed the effect either as percentage of all patients who had 
benefited from the intervention (which was not uniformely defined), or only in patients 
with pre-existing renal failure. Older studies usually did not evaluate the effect on renal 
function. 
 
Table 7.1 Reasons for exclusion. 
Reason for exclusion (not mutually exclusive) Number of publications (%) 
No consecutive inclusion of patients  23 (14) 
Renal function was not reported in sufficient detail, or only for 
subgroups  
 90 (56) 
  
Duration of follow-up less than three months  10 (6) 
At least 5% of patients was normotensive  6 (4) 
At least 5% of the patients had any of the following: 
   - accidentally detected renal artery stenosis 
   - non-atheromateous etiology  
   - re-stenosis of previously successfully treated lesion(s) 
   - stenosis in a transplant kidney 
 20 (12) 
  
  
  
  
A more recent study was available from the same research group    5 (3) 
Full text article could not be retrieved  12 (7) 
Less than 20 patients underwent revascularization  10 (6) 
Article did not report a patient series of revascularization  6 (4) 
  
Total 162 
 
Characteristics of studies 
Characteristics of patients and procedures and the outcome of the included studies are 
summarized in Table 7.2.  
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Table 7.2 (continued) 
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Setting 
All but three studies were performed in departments of internal medicine/ 
nefrology6,8,11-22 or radiology.23-27 In five studies this information was lacking.28-33 We 
qualified three studies as RCT,8,15,18 fifteen as prospective 
observational7,9,12,13,16,17,20-22,25,27,30-33 (among which the study by Webster and all.16 
which is sometimes refered to as a RCT eventhough not all patients were randomised) 
and ten as retrospective studies.6,11,14,19,23,24,26,28,29,34 
Patients 
The average age of the patients in the included studies varied between 53 and 71 
years. In most reports males and females were about evenly presented, although in ten 
65% (or more) of the participants were male.6,7,11,12,14,15,18,25,29,32 Average serum 
creatinine before intervention varied from high-normal to evidently increased 
(101-216 µmol/l). According to the average blood pressure values at baseline, blood 
pressure was reasonably controlled (RR<160/90) in four studies,17,29,33,34 in all others, 
however, blood pressure was markedly elevated. The indication for the intervention was 
usually hypertension13,15,16,19 or a combination of hypertension and the prevention of 
renal function decline;6,17,18,20,23,28,31,33 in three studies a minority of patients (9-23%) 
underwent intervention because of flash pulmonary edema.20,23,31 The prevalence of 
diabetes mellitus varied between 0 and 41%; rather remarkably, in nearly 25% of the 
included studies the prevalence of this main competitive explanation of renal function 
deterioration was not reported.6,7,11,12,14,16,27,31 
Lesion characteristics 
In all studies intervention was done only when the renal artery lumen was reduced by at 
least 50%. The actual cut-off, however, varied between 50 and 75%, and in seven 
cases additional abnormalities were required like a certain renal artery pressure 
gradient19-21,30,34 or some indication of decrease of function of the affected kidney.15,33 
Three studies excluded bilateral disease,9,15,22 all others included both patients with 
unilateral and bilateral renal artery stenosis, the prevalence of bilateral disease varying 
between 6 and 62%. Intervention of renal artery stenosis in a solitary kidney was not 
often applied in most series (0-9%), with the exception of the study by Canzanello et al. 
in which in 31% of the participants a procedure in diseased renal artery supplying a 
solitary kidney was performed.6 In thirteen out of the nineteen series that subdivided 
lesions according to their location within the artery (ostial vs. non-ostial), ostial lesions 
were more prevalent.   
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Procedures 
The procedures applied in the series were PTRA in four,6,11,12,14 PTRA plus stenting in 
six,21,25,29,31,33,34 primary stenting in five,19,20,22,30,32 PTRA or primary stenting or a 
combination of PTRA and stenting in eight7,8,15,18,23,26,27,32 and PTRA or surgery in four 
studies.9,16,17,35 Primary success rate was below 85% in four reports6,8,12,24 and above 
90% in the rest, exceeding 95% in the majority of these. The definition of primary 
success differed widely presumably affecting the reported rates. Restenosis has been 
actively looked for in thirteen out of the 28 studies, and was present in 11-48% of the 
cases. Again, also the definition of restenosis varied. Adverse event rates were reported 
to be 15% or less, three studies excepted with rates of 17%8, 23%34 and 29%.24  
Follow-up measurements 
Follow-up measurements were performed at regular intervals in 21 
studies7-9,12-18,20,22,23,25,27,29-34 and only at begin and end in seven studies.6,11,19,21,24,26,28 
Two studies explicitly mentioned only to have performed follow-up measurements in 
patients in whom the intervention was qualified as technically satisfactory.6,21 The 
percentage of participants in which follow-up was obtained was rather low (<85%) in 
many studies.6,7,11,14,16,25,29,32 Even more distressingly, a number of studies did not 
mention the number at follow-up at all, or only provided values of participants that had 
completed follow-up.12,24,27 
Quality of study 
The quality of studies varied a great deal, with a median quality score of twelve 
(interquartile range 11-14). (Table 7.3). None of the studies obtained the maximum 
score of 25, mainly because of loss of points in the categories “internal validity-bias” 
(which contained issues like blinding , statistical analysis and outcome measurement), 
“internal validity-confounding” (which contained items on selection and allocation of 
patients, confounding and (handling of) lost-to follow up) and “power”. All three RCT’s 
obtained scores above the median. 
Clinical outcome 
The average effect of intervention on renal function as estimated by random effect 
modelling was a decrease of serum creatinine concentration by 5 (0-10) µmol//l (Figure 
7.1). However, the change of creatinine after intervention differed greatly between the 
individual studies and the Q statistic provided evidence of heterogeneity between 
studies (p=0.01). The effect of study characteristics on the effect of intervention is 
shown in Figure 7.2. The length of the follow-up period and study design (prospective 
vs. retrospective) seemed to affect the estimation of the effect of intervention on renal 
function. However, since in our dataset retrospective studies usually had a longer 
follow-up period, it is impossible to untangle these two effects. Renal function at 
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baseline (serum creatinine above or below median of 143 µmol/l), type of intervention 
(in >60% of the patients PTRA only vs. >60% of the patients primary stenting or PTRA-
assisted stenting), publication year (before or after the median year 1998), number of 
participants (more or less than the median number of 62), and study quality (more or 
less than the median score of twelve) seemed to have no effect on the estimation, 
although the precision of the estimation seemed higher in studies with a higher quality 
score. Because of incomplete figures on prevalence of diabetes mellitus, lesion 
characteristics (ostial vs. non-ostial disease, unilateral vs. bilateral involvement) and re-
stenosis, we were unable to investigate the role of these variables in heterogeneity of 
the effect size.  
 
Table 7.3 Quality Index Score. 
Author 
  
Reporting
  
External 
validity 
Internal validity 
  
Power 
  
Overall 
score 
   bias confounding   
Canzanello et al.6 6 1 2 0 0 19 
Greminger et al.11 5 1 2 0 0 8 
Weibull et al.9 9 0 3 2 0 14 
Rodriguez-Perez et al.12 6 3 1 0 0 10 
White et al.13 6 0 3 0 0 9 
Bonelli et al.24 8 3 2 0 0 13 
Jensen et al.14 6 1 2 0 0 9 
Iannone et al.34 7 3 2 0 0 12 
Blum et al.25 6 1 2 0 0 9 
Plouin et al.15 9 2 4 2 0 17 
Tuttle et al.29 6 2 3 0 0 11 
Webster et al.16 7 1 4 0 0 12 
Henry et al.28 8 3 2 0 1 14 
Rocha-Singh.30 7 3 2 0 0 12 
Symonides et al.17 8 0 3 1 0 12 
Van de Ven et al.8 8 2 4 2 0 16 
Van Jaarsveld et al.18 9 2 4 2 0 17 
Bloch et al.19 5 3 2 0 0 10 
Ahmadi et al.26 7 3 2 1 0 13 
Dorros et al.31 6 3 2 0 5 16 
Ziakka et al. 7 6 3 2 0 0 11 
Henry et al. 32 8 0 3 0 0 11 
Kennedy et al. 20 6 2 3 1 1 13 
Ramos et al. 21 9 1 2 1 0 13 
Soulez et al. 27 6 1 3 1 0 11 
Zeller et al. 33 9 2 4 1 1 17 
Coen et al. 22 7 2 3 0 0 12 
Sivamurthy et al. 23 9 3 3 1 0 16 
       
Maximum obtainable 9 3 5 3 5 25 
Median (IQR) 7 (6-8) 2 (1-3) 3 (2-3) 0 (0-1) 0 (0-0) 12 (11-14) 
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Figure 7.1 The change of creatinine after intervention.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Influence of study characteristics on the estimation of the effect of renal outcome after 
intervention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unfortuanately, creatinine clearance was estimated in only ten studies and could 
therefore not be investigated. In Figure 7.3 the effect size (difference in creatinine) is 
plotted against the standard error, a so-called the funnel plot, which aims to investigate 
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the likelihood of publication bias. Considering the symmetric appearance of the “funnel”, 
the chance of (important) publication bias seems low. 
 
Figure 7.3 Funnel plot. 
The effect size (difference in creatinine) is plotted against the standard error of the effect size with 
pseudo 95% confidence limits. 
Discussion 
Since the introduction of renal artery patency restoration, a large number of 
observational studies have been published on the clinical outcome after various 
interventions. Salvage of renal function is a relatively new aim of revascularisation and 
was often not evaluated in older series. Many studies that did evaluate renal function 
and were potentially suitable for our meta-analysis, reported data in a way that 
prevented evaluation of change of serum creatinine. Review of 28 published series, with 
a total of 3582 subjects, indicated that renal patency restoration in patients with 
atherosclerotic renal artery stenosis and hypertension may lead to a small, yet 
statistically significant, improvement of renal function. The clinical relevance of this 
benefit, if any, remains to be established.  
 
In order to value our findings some methodological issues need to be discussed. Firstly, 
in any meta-analysis point estimates of the effect size from the included studies will 
differ. This can occur by “sampling error” (i.e. the true effect is the same in the each 
study), but usually variability exceeds that expected from sampling error only. In the 
latter case, effect size estimates are said to be “heterogeneous”. Heterogeneity in 
systematic reviews may occur because of differences, artefactual or real, in treatment 
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effect across the different studies. Whereas artefactual differences only hamper 
interpretation, real differences provide the possibility of studying effect-modification. In 
the present report, heterogeneity proved to be non-negligible despite stringent inclusion 
criteria. Presumably, this should be attributed, at least in part, to artefactual differences, 
since there was substantial variation in baseline renal function, lesion characteristics, 
procedures, follow-up period and numbers lost to follow up. Subgroup analyses 
provided no convincing evidence that type of intervention, year of publication or study 
design (retrospective vs. prospective) were involved in heterogeneity. It should be 
noted, however, that many other predefined variables (like for example presence of 
diabetes mellitus and numbers lost to follow up) could not be studied because they were 
inadequately, if at all, reported. It would therefore be desirable for future pooling of data 
that authors would conform to reporting standards, such as the guidelines formulated by 
the American Heart Association.36 It is well known that extreme heterogeneity may 
prevent meaningful conclusions although there is no consensus as to which degree of 
heterogeneity is still acceptable. By the use of random effects modeling, which allows 
variation in the underlying effect size between studies to be taken into account, we 
diminished this effect at least partly. The estimation of the size of the effect, however, 
should be interpreted cautiously especially since the quality of many studies was rather 
disappointing. Secondly, from a methodological point of view, it would have been better 
to compare the change in creatinine between patients (randomly allocated) to active 
treatment and patients treated with (maximum) conservative therapy in stead of change 
of serum creatinine in an active treatment group only. However, only three such trials 
exist.15,16,18 Up to date, two meta-analyses have been published that considered these 
reports.37,38 The study by Nordmann et al. could not pool data with respect to renal 
function because they were reported in different ways in the original reports. The study 
by Ives et al. gathered data from the authors and found (by pooling data from the 
studies by Plouin et al. and Van Jaarsveld et al.) a small advantage of angioplasty over 
conservative treatment (difference in serum creatinine of 6 µmol/l). This difference was, 
however, not statistically significant. The analysis was, however, seriously 
underpowered since it was based on a comparison between 75 patients who underwent 
angioplasty and 72 who were treated by drugs only (of which 22 or 31% had undergone 
angioplasty within the follow-up period). Although inferior from a methodological point of 
view, observational studies do have a specific role in medical effectiveness research. 
Patients enrolled in RCT’s often differ from the average patients in clinical practice. 
Indeed, the setting and the applied intervention in a observational study probably 
approximate clinical practice better than that in the RCT. In accord with the meta-
analysis by Ives et al.,38 our analysis, showed a small, yet statistically significant, benefit 
with respect to renal function.  
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Conclusion 
This systematic review adds a new piece to the existing evidence suggesting that it is 
unlikely that intervention will lead to major improvement of renal function. 
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Main findings in perspective 
The studies in this thesis describe several diagnostic (Chapter 2 and 3), 
pathophysiological (Chapters 4, 5 and 6) and therapeutic aspects (Chapter 7) of renal 
artery stenosis. The current chapter links up these different aspects and discusses how 
our findings add to existing knowledge on the discrimination between patients with and 
without renal artery stenosis and on the functional significance of renal artery stenosis. 
Why should renal artery stenosis be diagnosed? 
Before discussing in greater detail how to diagnose renal artery stenosis, it is necessary 
to highlight why we should diagnose renal artery stenosis in the first place. Clinically, 
this is useful only when the management of the condition is beneficial, i.e. when the 
pros outweigh the cons. Whether this is the case for renal artery stenosis is not beyond 
dispute. Advantages of timely diagnosing any disease may be that the institution of 
therapy directed specifically at the cause relieves symptoms or that undesirable 
consequences are averted. Disadvantages include costs and the possibility of 
complications related to the diagnostic procedures.  
 
To what extent is the timely diagnosis and treatment of renal artery stenosis beneficial? 
Fairly seldom, renal artery stenosis may present as hypertensive urgency of emergency 
or, in case of bilateral (near-) occlusive renal artery disease, acute (“flash”) pulmonary 
edema. In most cases, however, the only signs of renal artery stenosis are systemic 
hypertension and renal dysfunction. Both are independent risk factors for morbidity and 
mortality. The effect of mechanical treatment of the stenosis on hard end points like 
end-stage renal disease and cardiovascular morbidity and mortality, has not been 
investigated so far. While this information is urgently needed, the conduct of a well-
designed randomised clinical trial with adequate power and follow-up will require an 
enormous effort. Recently, such a trial (the CORAL study) has been approved and is 
currently undertaken although its results will not become available in the near future.1 
With respect to the effect on blood pressure, early reports of percutaneous angioplasty 
in renal artery stenosis already indicated that the chance of clinical success of 
revascularisation depends on the etiology of renal artery stenosis. In Caucasians, the 
abnormality is usually caused by atherosclerosis (75%) or fibromuscular dysplasia 
(25%). Other causes, like Takayasu’s arteritis, external compression and radiation 
injury, comprise less than one percent. The reported cure rates of treatment in patients 
with fibromuscular dysplasia reaches 50% and in many other patients blood pressure 
falls to such an extent that less medication is needed.2 In atherosclerosis, however, 
results are less marked. The effect of renal artery patency restoration in atherosclerotic 
disease on blood pressure and renal dysfunction has been compared to non-specific 
therapy (use of antihypertensive drugs) in three randomised trials.3-5 Meta-analysis of 
these studies found that patients who underwent revascularisation had a slightly lower 
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blood pressure and somewhat reduced antihypertensive drug requirement as compared 
to patients who were treated conservatively. No effect was found on renal function.6,7 
These trials have been criticized for non-negligible cross-over between groups and the 
fact that they did not apply stents, that may decrease the change of restenosis.3-5 Apart 
from these criticisms, the individual randomised clinical trials (and the meta-analyses) 
had a short follow-up and probably did not have enough power to draw conclusions with 
respect to renal function. Currently, a randomised clinical trial is being conducted in 
order to elucidate this issue, but it will take some time before its results will be 
disclosed.8 Therefore, we performed a meta-analysis (Chapter 7) of all available 
evidence the results of which suggests that with the current practice of patient selection 
it is unlikely that intervention will lead to major improvement of renal function within one 
to two years after intervention. However, it was not possible to evaluate long-term 
effects. It seems too early, therefore, to give a definite answer to the question whether 
revascularisation therapy can avert undesirable (long term) consequences.  
 
Pursuing a diagnosis of renal artery stenosis may also provide disadvantages. Renal 
angiography, which is still the gold standard for diagnosis, is expensive amounting 
€1721 according to a recent calculation.9 More importantly, it brings about a (small) 
chance of potentially serious complications like atheromatous embolization of the 
kidneys, renal artery dissection, radiocontrast-induced nephropathy, retroperitoneal 
bleeding, femoral pseudoaneurysm and hematoma requiring surgical exploration. The 
chance of such serious complications is low and depends also on underlying morbidity. 
In the RADISH study, which compared computed tomographic angiography (CTA) and 
magnetic resonance angiography (MRA) to conventional digital subtraction angiography 
(DSA), the rate of serious adverse events was 0.7% (three out of 402 patients, one died 
within 30 days after DSA, one allergic reaction to contrast agent and one dissection of 
the renal artery necessitating nephrectomy).10  
 
The question thus remains whether it is worthwhile to diagnose renal artery stenosis. 
This question is of course difficult to answer in general, because it depends also on the 
clinical context, like the number of functioning kidneys or structure and function of the 
poststenotic kidney(s). Yet, in our opinion, with the current state of knowledge, the 
answer should be a cautious “yes”. First of all, not diagnosing renal artery stenosis 
would imply that also patients with FMD, who have a fair chance of cure, are denied 
causative therapy. As described in Table 1.1 in Chapter 1, these patients cannot be 
readily distinguished from patients with atherosclerotic disease on the basis of simple 
characteristics like age and sex. Secondly, in patients with atherosclerotic disease 
revascularisation may lead, on average, to a modest fall in blood pressure and some 
reduction in medication use. The effect on long-term renal outcome, however, is not yet 
known. The effect of this slight improvement in blood pressure and reduced need for 
medication, may be greater than suggested by absolute numbers. It is a well known 
phenomenon that results from clinical trials should be translated cautiously to every day 
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practice. Clinical trials tend to be executed in specialized institutions. Such institutions 
may treat a highly selected group of patients that may contain more unusual or difficult 
“cases” who may have different a priori chances of success. On the other hand, the 
achievements of interventional radiologists (or vascular surgeons) in these centres may 
be better compared to those in routine clinical practice. Participants in clinical trials are 
under tighter control than would normally occur in general care. Further, consenting 
patients may have different values with respect to health than refusers.11 In which 
direction the sum of these factors will influence treatment outcomes outside trials, is 
hard to tell. Presumably, both the tighter control and the restriction of the evaluation of 
outcome to patients who consented to participation in a clinical trial, lead to a better 
compliance with therapy in clinical trials than in every day practice. The effect of 
revascularisation is compliance-independent, whereas the use of drugs is obviously not. 
Adherence to treatment declines with the number of prescribed pills.12,13 It may 
therefore very well be that in general practice the reduced need for antihypertensive 
drugs after mechanical treatment results in greater differences in blood pressure 
between patients treated with revascularisation and those conservatively treated than in 
clinical trials. This may be of importance since in the prevention of cardiovascular 
disease and renal failure, millimetres do count.14,15 Of course, before advocating an 
invasive treatment solely on the basis of this argument, patient preferences, alternative 
strategies (for example, the promotion of therapy-adherence and/or lifestyle 
modification) and cost-effectiveness considerations will have to be taken into account. 
Thirdly, revascularisation may have beneficial effects on vascular and renal function 
through mechanisms other than blood pressure reduction or renal function salvage. In 
studies investigating split renal function in unilateral disease, revascularisation reversed 
the state of hypoperfusion through the poststenotic kidney and the hyperperfusion 
through the kidney contralateral to the stensosis without any change in average kidney 
function.3,16-18 Furthermore, endothelial function may improve after angioplasty.19 
Provided that these changes prove to be long-lasting, they may affect long–term 
outcome.  
How to identify patients with renal artery stenosis?  
Usually, suspicion of renal artery stenosis is raised by the presence of severe 
hypertension in association with one or more clinical clues.20,21 When there is a high 
degree of suspicion, renal angiography may be performed. During the past decade, 
most research concerning the diagnosis of renal artery stenosis has focused on the 
development of accurate non-invasive diagnostic tests to be used in patients with some 
degree of clinical suspicion of renal artery stenosis. Initial reports regarding the value of 
MRA, CTA and renal duplex ultrasonography for this purpose ranged from positive to 
very enthusiastic.22 As a consequence, consensus guidelines had already qualified 
MRA, CTA and renal duplex as acceptable screening tests before evidence from well-
designed trials became available.23,24 To our knowledge, only one large prospective 
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observer-blinded study compared MRA and CTA to the gold standard, and found that 
these tests do not live up to their expectations and should not be used, neither as 
diagnostic tests nor as screening tests. This conclusion is based primarily on the low 
sensitivity of the diagnostic modalities (CTA 64%, MRA 62%); specificity was adequate 
(CTA 92%, MRA 84%).10  
 
Based on the disappointing performance of non-invasive tests, we studied whether the 
efficiency of the use of renal angiography for the diagnosis of renal artery stenosis could 
be improved on the basis of clinical clues and risk factors easily obtainable through 
anamnesis, physical examination or simple diagnostic tests. (Chapter 2) To this end, we 
assessed the prevalence of clinical clues and risk factors for cardiovascular disease in 
general in patients who underwent renal angiography because of a high clinical 
suspicion. This restricts the validity of our findings to patients who present with similar 
conditions, i.e. patients between 18 and 75 years of age with persistent hypertension 
and with at least one clinical cluea who are referred to secondary/tertiary care centres. In 
this group of patients, the prevalence of renal artery stenosis was 20%. Of all clues and 
risk factors, only a higher age, a high pulse pressure, recent onset of hypertension 
(within the two years before referral), smoking, widespread atherosclerosis and a length 
difference between the kidneys independently predicted the presence of renal artery 
stenosis. Four out of the six predictors (age, pulse pressure, smoking and 
atherosclerosis elsewhere) are among the usual clues for any manifestation of 
atherosclerosis, which is in the majority of patients the cause of the disease under 
study. The other two predictors seem to be more related to the specific features of 
renovascular hypertension (more sudden onset of hypertension) and consequences 
(reduction of renal volume). When these factors are known, the probability of renal 
artery stenosis can be predicted through summation of the scores associated with the 
presence (and the magnitude) of the predictors. This probability may be used as a guide 
to whom one should refer for angiography. One may decide to perform angiography 
only when the probability of renal artery stenosis is higher than a certain threshold 
value. For example, when a threshold value of 10% is chosen, sensitivity and specificity 
for the detection of stenosis are 93% and 38% respectively. Would this rule have been 
applied to our cohort, the number of angiographies could have been reduced by 38%. 
More efficient use of renal angiography may lead to a reduction in costs, and possibly 
also absolute complication rate. Inevitably, some patients with renal artery stenosis are 
                                                          
a persistent hypertension despite (at least) two antihypertensive drugs or diastolic blood pressure 
>120 mmHg on single-drug therapy, malignant or accelerated hypertension, sudden onset or 
worsening of hypertension, severe hypertension before the age of 30 or after the age of 60, 
unexplained (or sudden onset of ) renal dysfunction, angiotensin converting enzyme (ACE)-inhibitor 
induced renal function deterioration, renal bruit, unilateral small kidney, extensive (atherosclerotic) 
occlusive disease, suspicion of restenosis after previously successfully treated renal artery lesions, 
smoking, high serum cholesterol concentration, low serum potassium concentration, and/or left 
ventricular hypertrophy 
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missed when using this cut-off value. Would the rule have been applied to our cohort, 
11% of the stenosis would have been missed. Whether this is a major disadvantage, 
depends on whether this concerns patients who would benefit from specific treatment, 
which is currently unknown. Two published models proposing a diagnostic strategy as to 
whom should be subjected to angiography, namely the prediction rule from the 
DRASTIC study25 and the Mann-Pickering strategy,21 are commonly referred to. Our 
model differs from these two in several respects. The application of the DRASTIC rule is 
restricted to patients with therapy resistant hypertension (defined in that study as 
hypertension despite the use of at least one drug in patients under the age of forty and 
at least two drugs above the age of forty) and/or patients with ACE-inhibitor induced 
renal function deterioration. We believe that clinicians are inclined to suspect renal 
artery stenosis in broader categories of patients with hypertension. The implementation 
of the Mann-Pickering strategy is hampered by the need for high quality screening tests 
which are, as discussed previously, currently unavailable. In this respect, our model 
may be better fitted for daily practice in the physicians office than previous models 
although we do acknowledge that our model still has to be validated prospectively. Such 
evaluation should preferably also include the benefit of the diagnostic strategy. In other 
words: how many of the patients in whom renal artery stenosis is detected by the 
prediction model (and confirmed by angiography) benefit from the diagnosis (through a 
favourable response to revascularisation), and how does this relate to the number of 
patients who benefited from angiography but were not detected by the prediction model.  
 
Before proceeding to external validation, we wanted to test whether the diagnostic 
performance could be further improved. Firstly, we evaluated whether the measurement 
of renal lengths was indispensable for accurate prediction. In order to obtain this 
information, additional testing, namely renal ultrasound examination, has to be 
performed with associated costs. Ultrasound data, however, did not improve the model 
substantially, because this test was usually only abnormal (i.e. a length difference 
between the kidneys was found) in patients already labelled as high-risk on the basis of 
the other five predictors. Secondly, we tested whether replacing rather crude 
measurements of predictors by their more refined counterparts would improve 
diagnostic accuracy. (Chapter 3) We substituted the number of vascular beds with overt 
atherosclerotic involvement (as assessed by anamnesis, medical history and physical 
examination) for IMT of the common carotid artery and/or PWV. It has been shown 
repeatedly that both IMT and PWV are associated with cardiovascular disease and 
traditional risk factors.26-30 Office pulse pressure (as calculated from the three 
measurements of systolic and diastolic blood pressure during a visit to the outpatient 
clinic) was replaced by ambulatory measurements (ABP) of pulse pressure (PP) during 
24 hours, which have higher reproducibility than office blood pressure measurements 
and predict cardiovascular risk over and above conventional blood pressure 
measurements.31 Each of the newly considered predictors was related to renal artery 
118⏐Chapter 8 
stenosis, and they were also interrelated. Somewhat to our surprise, however, none of 
these more sophisticated measurements improved the predictive accuracy of the model.  
 
Our findings indicate that in a pre-selected population with an a priori risk of 20%, it is 
feasible to detect patients with a low change (<10%) of renal artery stenosis on the 
basis of easily obtainable predictors, provided that our model will prove to be valid in 
other populations. These patients may then be exempted from angiography. Further 
improvements in diagnosing renal artery stenosis may be obtained if a screening test 
test with good test characteristics would become available. Specifically, a low negative 
likelihood ratio is essential, because this will affect the decision (not) to perform 
angiography, by decreasing (post-test) probability of renal artery stenosis in case of a 
negative test result. A high positive likelihood ratio, on the other hand, increases (in the 
event of a positive screening test) the (post-test) chance of renal artery stenosis. Yet, 
assuming that that our model is valid, the selection of patients by our model may lead to 
a pre-(screening)test chance that may be as high as 30%. Since angiography will 
presumably also be performed in case of 30% chance of renal artery stenosis, the use 
of such screening test, which further increases the chance of renal artery stenosis, will 
not affect the decision to perform angiography,  
The functional significance of atherosclertic renal artery stenosis  
One of the most intriguing and still unresolved issues in the pathophysiology of 
atherosclerotic renal artery stenosis is why even advanced disease does not always 
have clinical consequences. In experimental models of renovascular hypertension, the 
relationship between renal artery stenosis and hypertension is straightforward. 
Narrowing of the renal artery beyond a certain threshold leads to fall in blood flow 
through the kidney. This is associated with increased renin secretion, which, via the 
effector hormone angiotensin II leads to relative preservation of the glomerular filtration 
rate in the affected kidney, abeit, at the cost of high blood pressure.32,33 In humans, the 
relationships between atherosclerotic renal artery stenosis, hypertension and renal 
dysfunction are complex. Renal artery stenosis may occur alone, or in association with 
either hypertension or renal dysfunction, or both.34 Consequently, the mere fact that a 
renal artery stenosis is detected in a patient with hypertension does not automatically 
mean that that person is suffering from renovascular hypertension. Several scenarios 
may pertain: the renal artery stenosis may cause and sustain hypertension, or the 
patient may have been suffering from essential hypertension and on top of that a renal 
artery stenosis has developed. In fact, it is even more complicated: long-standing 
hypertension irrespective of its cause leads to secondary changes which may sustain 
hypertension even when the causative factor is removed. The same line of reasoning 
applies to renal dysfunction and leads to diametrically opposed opinions on the 
significance of renal artery stenosis. Based on the fact that many patients reaching end-
stage renal disease with renal artery stenosis have no (other) apparent explanation for 
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renal failure, some authors argue that it is likely that renal artery stenosis accounts for 
14-20% of the patients entering dialysis programs.35 Others say that it is an innocent 
bystander with little effect on renal function since in retrospective series remarkably few 
patients with incidentally detected renal artery stenosis seem to progress to advanced 
renal failure.36,37 With these considerations as a starting point, we will now evaluate the 
pathophysiological aspects that we studied and reported in this thesis. In experimental 
models, activation of the renin-angiotensin system and reduction of renal blood flow are 
cornerstones in the pathophysiology of renovascular hypertension. In the search for an 
explanation why renal artery stenosis seems to lack functional consequences in a 
sizable proportion of patients, we decided to concentrate on these aspects in humans.  
 
In the study presented in chapter 4, we were interested in genetic aspects. Besides the 
renin-angiotensin system, also endothelial derived nitric oxide may be important in renal 
blood flow regulation in patients with renal artery stenosis38 and therefore we 
investigated polymorphisms in genes from the renin-angiotensin system 
(angiotensinogen Met235Thr (AGT M235T), the angiotensin converting enzyme 
insertion/deletion (ACE I/D) and the angiotensin II type 1 receptor A1166C (AT1R 
A1166C) polymorphisms) and from the endothelial nitric oxide synthase enzyme (eNOS 
Glu298Asp polymorphism). Polymorphisms are frequently occurring variations in the 
human genome. By definition, the frequency of the allele with the lowest prevalence is 
higher than 1%, but the occurrence rate may vary between populations. In chapter 4 we 
report an association between the Asp allele of the eNOS Glu298Asp polymorphism 
with atherosclerotic artery disease. However, the prevalence of this allele differed also 
significantly between patients with patent renal arteries and both normotensive and 
hypertensive controls. Therefore, it is likely that the Asp-allele predisposes not so much 
to renovascular disease in particular, but more to systemic atherosclerosis. Association 
studies, like the one we performed, may provide evidence of a relationship between a 
polymorphism and a disease. This (statistical) relationship can be brought upon by three 
situations. First, the allele itself directly affects the expression of the phenotype. Second, 
the allele is in linkage disequilibrium with another allele (in the same gene or one at 
close distance) that is responsible for the effect. Third, the association is brought about 
by confounding or selection bias. The fact that the association was also apparent in the 
two control groups, makes the third situation unlikely. Our results do not allow to 
differentiate between the first and the second situation. Nevertheless, considering the 
importance of endothelium-derived nitric oxide in atherosclerosis, our findings fit very 
well in the theoretical framework of atherosclerotic disease and merit further research 
into the mechanisms whereby altered nitric oxide production in conjunction with other 
cardiovascular risk factors may cause systemic atherosclerosis. The polymorphisms in 
genes of the renin-angiotensin system that we studied, were not associated with renal 
artery disease. Although our findings may provide valuable insights into the 
pathophysiology of systemic atherosclerosis, the investigated genetic variations do not 
seem to be involved in pathophysiology of renal artherosclerotic disease per se.  
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In order to assess whether renal blood flow studies and key-players of the renin-
angiotensin system are involved in determining the functional consequences of renal 
artery disease, we must first be informed about the normal situation. In other words, the 
situation in patients without any renal artery abnormalities, must be known. Preferably, 
we would have liked to investigate young, healthy, normotensive patients. However, in 
order to assess renal blood flow and hormonal activity per kidney, selective arterial and 
venous catherisation will have to be performed. Obviously, it is not ethical to subject 
patients without any suspicion of renal artery stenosis to the risks of such an invasive 
procedure. The second best control group, consisting of patients with hypertension 
without any renal artery abnormalities, was investigated in chapter 5. We showed that 
differences in renal blood flow between the two kidneys were common but unrelated to 
the level of activity of the renin-angiotensin system. The implicit assumption underlying 
some diagnostic tests for renal artery stenosis, like renal scintigraphy, is that, in the 
absence of a hemodynamically significant renal artery stenosis, blood flow through the 
kidneys will be roughly symmetrical. Indeed, we found that the presence of a clear-cut 
difference of renal blood flow between the kidneys was associated with a false-positive 
result of renal scintigraphy and this may provide a partial explanation for the poor 
predictive ability of renal scintigraphy for the diagnosis of renal artery stenosis. In 
chapter 6 we examined selective renal blood flow in patients with unilateral 
atherosclerotic disease. In these patients, at least in the ones with high grade disease, 
asymmetry was expected. Strikingly, we found that the prevalence of asymmetry in 
these patients was virtually similar to that in patients without any renal artery 
abnormalities. Further, in patients with asymmetry, the activity of the renin-angiotensin 
system was higher, both in patients with low and high grade disease. Both studies in 
patients with and without renal artery stenosis indicate that the relationship between 
(grade of) stenosis in the renal artery, renal blood flow and activity of renin angiotensin 
system is more complex than hitherto assumed. Only in patients with renal artery 
stenosis, asymmetry was associated with increased activity of the renin angiotensin 
system. Possibly, this indicates that the determinants of asymmetry are, at least in part, 
dissimilar. The great majority of patients with high grade renal artery stenosis underwent 
revascularisation. Only in patients with symmetry of MRBF pulse pressure dropped 
whereas the decrease in mean arterial pressure after revascularisation was similar in 
the two groups. Since pulse pressure reflects arterial stiffness, this may indicate that in 
patients with asymmetry structural changes in the arterial vasculature may prevent 
changes in pulse pressure. It is probable that in atherosclerotic renal artery disease, 
structural and/or functional changes in the microvasculature are present. Whereas 
revascularisation may eliminate arterial luminal reduction, it is less likely that this will 
affect the pathophysiological conditions in smaller vessels.  
 
From a pathogenetic point of view atherosclerotic renal artery stenosis and 
fibromuscualar dysplastia represent entirely different diseases. Whereas atherosclerosis 
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affects both large and small vessels, FMD is considered to affect only large arteries. 
FMD may, therefore, be a “better model” for the development of renovascular 
hypertension (and renal dysfunction) than atherosclerotic renal artery stenosis. The 
prevalence of FMD, on the other hand, is lower. When an adequately sized group of 
patients with FMD is assembled in the Maastricht angiography cohort, renal blood flow 
studies in these patients might shed new light on the issue of asymmetry of renal blood 
flow.  
 
At the present time, the distinction between functional and non-functional stenoses does 
not seem to be possible. With this consideration in mind, it may be argued that we 
should aim at detecting only those patients with renal artery stenosis who have the 
potential to benefit from treatment. Research into this issue is complicated by the fact 
that revascularisation sometimes fails because of technical reasons, restenosis may 
interfere with the outcomes under study and the diagnosis may sometimes be reached 
at a time when secondary changes have already diminished the chance of a favourable 
outcome. While detecting reversible renovascular disease does not seem feasible, the 
reverse, i.e. identifying factors that preclude benefit in terms of blood pressure and renal 
function from therapy, may be a more achievable goal. Renal length less than nine 
centimetres and a (bilateral) high resistance index may be among such factors.39,40 
Future research will have to determine whether the presence of asymmetry of renal 
blood flow may be added to this list. The routine examination of these factors in a way 
easily applicable in clinical practice, may further reduce the number of patients 
subjected to angiography, while not precluding the chance of clinical benefit in others. 
 
The landscape of atherosclerotic renal artery disease has markedly changed over the 
past decade due to the new imaging modalities and improvements of revascularisation 
techniques. In spite of this, or perhaps because of this, the discussion on the optimal 
management causes much controversy among clinicians. This continuing dispute can 
only be settled by research into appropriate diagnostic and therapeutic strategies, and 
the studies described in this thesis may have added to this. 
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Summary 
Renovascular hypertension is considered to be the second most common cause of 
secondary hypertension. About one percent of all individuals with elevated blood 
pressure in the general population has a stenosis in one or more of their renal arteries. 
The presence of renal artery stenosis may lead to renovascular hypertension and renal 
dysfunction. Restoration of renal artery patency may, at least potentially, reverse 
hypertension and prevent (further) deterioration of kidney function. The relatively high 
prevalence of renal artery stenosis contrasts with our rather poor understanding of the 
interrelationships between renal artery lumen reduction, renal perfusion pressure and 
renal blood flow on the one hand and their alleged consequences hypertension and 
renal dysfunction, on the other. The studies that form the main body of this thesis 
investigated diagnostic ((chapter 2 and 3), pathophysiological (chapters 4, 5 and 6) and 
therapeutic (chapter 7) aspects of renal artery stenosis. These studies were designed 
and conducted to assess whether these aspects could 1) distinguish patients with renal 
artery stenosis from with moderate to severe hypertension without such a lesion and 2) 
shed light on the pathophysiology of renal artery stenosis and/or renovascular 
hypertension. The current chapter summarizes main findings from these studies.  
 
In chapter 2, we assessed the predictive power of established clinical clues1,2 and 
traditional cardiovascular risk factors for the diagnosis of renal artery stenosis in our 
cohort. We found that the majority of clinical clues had only limited predictive value. Six 
predictors were identified: age, pulse pressure, current or past smoking behaviour, 
onset of hypertension within two years, extra-renal atherosclerosis and a difference in 
kidney lengths. A model incorporating these six predictors achieved an optimism-
corrected area under the receiver-operating characteristic curve of 0.75. Hence, even 
though the value of established clinical clues for prediction of renal artery stenosis in 
common clinical practice is low, the number of patients undergoing renal angiography 
may be reduced with our model. Of course, before the use of our model can be 
recommended for clinical practice, the model should be validated in other population(s). 
 
In chapter 3, we investigated the hypothesis that the precision of predictions by the 
model presented in chapter 2 could be increased by replacing crude measurements of 
the predictors pulse pressure and extra-renal atherosclerosis by more refined 
counterparts (24-hour ambulatory pulse pressure and intima-media thickness (IMT) of 
the common carotid artery and/or aortic pulse wave velocity (PWV) respectively). Each 
of the newly considered predictors was related to renal artery stenosis, and they were 
also interrelated. Somewhat to our surprise, however, none of these more sophisticated 
measurements improved the predictive accuracy of the model. Our results, with respect 
to PWV and IMT, corroborate findings in populations at high risk as well as at low risk 
with respect to various manifestations of cardiovascular disease. IMT and PWV seem to 
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have no additional value in the prediction of cardiovascular disease over and above 
easily obtainable traditional risk factors.  
 
In chapter 4, we report a study on the association of four polymorphisms in candidate 
genes with atherosclerotic renal artery disease. It concerns the angiotensinogen 
Met235Thr, the angiotensin converting enzyme insertion/deletion, the angiotensin II 
type 1 receptor A1166C and the eNOS Glu298Asp polymorphisms. In this chapter, 
normotensive and hypertensive patients without a history of cardiovascular disease from 
a family practice served as external controls. No differences were found with respect to 
the polymorhisms in genes of the renin-angiotensin system. The Asp-allele of the 
endothelial nitric oxide synthase Glu298Asp polymorphism on the other hand, was 
associated with atherosclerotic renal artery stenosis with an odds ratio (95% confidence 
interval) of 1.44 (1.00-2.09) versus hypertensives with angiographically-proven patent 
arteries, of 1.89 (1.24-2.87) versus hypertensive family practice controls and of 2.09 
(1.29-3.38) versus normotensive family practice controls. However, this allele differed 
also significantly between patients with patent renal arteries and both normotensive and 
hypertensive controls. Since atherosclerotic renovascular disease is generally viewed 
upon as a local manifestation of systemic atherosclerotic disease our data support 
earlier observations in this respect. The absence of atherosclerotic lesions in renal 
arteries, namely, does not at all exclude the presence of atherosclerosis elsewhere in 
the vascular system and, indeed, nearly a quarter of the patients whose arteries turned 
out to be patent (after angiography) had experienced signs of extrarenal athero-
sclerosis. Moreover, it is likely that normotensive and hypertensive patients in a general 
care practice have lower amounts of (extra-renal) atherosclerosis than patients in an 
outpatient clinic of a secondary/tertiary referral hospital who are suspected of having 
renal artery stenosis. Thus, we hypothesize that the Asp-allele of the eNOS Glu298Asp 
polymorphism predisposes to (systemic) atherosclerosis.  
 
In chapter 5, we studied selective renal blood flow in the patients in our cohort without 
any renal artery abnormality. We found clear-cut left-right differences (“asymmetry”) in 
51% of the patients. Subjects with and without asymmetry did not differ in age, body 
mass index, blood pressure, creatinine clearance, renal volume or activity of the renin-
angiotensin system. Preliminary data suggest that there may be a relation between 
asymmetry and renal sympathetic nerve activity, which might point to the fact that the 
differences may be, at least partially, functional. The presence of asymmetry coincided 
with an increased rate of false-positive results on renal scintigraphy, a screening test for 
renal artery stenosis that is largely abandoned nowadays because of unfavourable test 
characteristics. The fact that asymmetry of renal blood flow is a frequent finding in 
severe hypertension underscores the importance of studying the function of both 
kidneys separately, since it cannot be assumed that they are functionally equal. 
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In chapter 6, we assessed selective renal blood flow in patients with unilateral 
atherosclerotic renal artery disease of varying severity (15-100% stenosis). Higher 
grades of luminal reduction coincided with an increased difference in mean renal blood 
flow (MRBF) between the stenosed kidney and the contralateral kidney. However, in 
half of the patients with high grade stenosis, flow through the kidneys was similar or 
even higher in the kidney with the stenosis than in the contralateral one. Further, 
patients with asymmetry had greater activity of the renin-angiotensin system regardless 
of the degree of stenosis. The great majority of patients with high grade disease 
underwent revascularisation. The decrease in mean arterial pressure after this 
procedure was similar in both groups, but only in patients with symmetry this was 
accompanied by a reduction of pulse pressure.   
 
In chapter 7, we performed a meta-analysis of all available evidence on the effect of 
revascularisation on intermediate renal outcome as measured by a change of 
creatinine. Review of 29 published series, with a total of 3701 subjects, indicated that 
although average change of creatinine after intervention differed greatly between the 
individual studies, renal patency restoration in patients with atherosclerotic renal artery 
stenosis and hypertension may lead to a small, yet statistically significant, benefit with 
respect to renal function. It is however unlikely that intervention will lead to major 
improvement of renal function.  
 
In chapter 8 the results of the studies mentioned above are discussed and put in 
perspective.  
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Samenvatting 
Van alle personen met hypertensie (‘hoge bloeddruk’) in de algemene bevolking heeft 
ongeveer één procent een stenose (‘vernauwing’) in een of meer van hun nierarteriën 
(‘nierslagaderen’). De aanwezigheid van zo’n nierarteriestenose kan leiden tot 
(renovasculaire) hypertensie en vermindering van de nierfunctie. Het is mogelijk de 
doorgankelijkheid van de aangedane nierarterie te herstellen, met als doel de 
bloeddrukregulatie te verbeteren en te voorkomen dat de nierfunctie (verder) 
verslechtert.  
 
De relatief hoge prevalentie van nierarteriestenose staat in scherp contrast met de 
hiaten in onze kennis van enerzijds de relaties tussen afname van het lumen van de 
nierarterie, de  perfusiedruk en de nierdoorbloeding en anderzijds de uiteindelijke 
consequenties, te weten hypertensie en afname van de nierfunctie. De studies welke in 
dit proefschrift worden beschreven, bestudeerden diagnostische (hoofdstukken 2 en 3), 
pathofysiologische (hoofdstukken 4, 5 en 6) en therapeutische (hoofdstuk 7) aspecten 
van nierarteriestenose. Deze studies werden opgezet en uitgevoerd om te weten te 
komen of met behulp van deze aspecten: 1. in een ziekenhuispopulatie van patiënten 
met matig tot ernstige hypertensie een onderscheid kan worden gemaakt tussen 
degenen met een nierarteriestenose en degenen die deze afwijking niet hebben en 2. 
meer inzicht verkregen kan worden in de pathofysiologie van nierarteriestenose en 
renovasculaire hypertensie. 
 
In het tweede hoofdstuk wordt de studie beschreven waarin de waarde van veel 
gebruikte klinische kenmerken1,2 en de traditionele cardiovasculaire risicofactoren werd 
bepaald bij het voorspellen van het vóórkomen van nierarteriestenose. De analyses 
lieten zien dat de overgrote meerderheid van deze wijd aanvaarde klinische kenmerken 
nagenoeg geen voorspellende waarde hadden. Het vóórkomen van nierarteriestenose 
bleek wel samen te hangen met de volgende zes variabelen: leeftijd, polsdruk, roken of 
in het verleden gerookt hebben, recent (<2 jaar) ontstaan van hypertensie, 
atherosclerose in andere vaatbedden en een verschil in lengte tussen de twee nieren. 
Een model met deze zes variabelen behaalde een gecorrigeerde oppervlakte onder de 
receiver-operating characteristic curve van 0.75. Aldus lijkt het met behulp van dit model 
mogelijk een redelijke uitspraak te doen over welke patiënten een zeer lage  kans 
hebben op een nierarteriestenose en bij gebruik van het model kan het aantal patiënten 
dat een nierangiografie moet ondergaan sterk gereduceerd worden. Echter, voordat  dit 
model in de praktijk gebruikt kan worden, moet het gevalideerd worden in andere 
populaties. 
 
In het derde hoofdstuk hebben we getracht het model dat gepresenteerd werd in 
hoofdstuk 2 te verbeteren door verfijndere technieken te gebruiken om de polsdruk en 
extra-renale atherosclerose te kwantificeren. Hiervoor gebruikten we respectievelijk 
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ambulante bloeddrukregistratie en metingen van intima-media dikte (IMT; a. carotis 
communis) en pulse wave velocity (PWV; traject a. carotis communis – a. femoralis). 
Alhoewel deze metingen gerelateerd waren aan het vóórkomen van nierarteriestenose, 
verbeterden ze de voorspellingen van het model uit hoofdstuk twee niet. Dit is in lijn met 
recente studies waarin IMT en PWV cardiovasculaire ziekten niet beter lijken te 
voorspellen dan veel eenvoudiger te bepalen traditionele risicofactoren.  
 
In hoofdstuk 4 werd de associatie tussen nierarteriestenose op basis van 
atherosclerose en vier genetische polymorfismen in kandidaat-genen getoetst. Het 
betroffen polymorfismen in de angiotensinogeen (Met235Thr), the angiotensin 
converting enzyme (insertion/deletion), the angiotensine II type 1 receptor (A1166C) 
and the eNOS (Glu298Asp) genen. Normotensieve en hypertensieve patiënten uit een 
huisartspraktijk dienden als extra controle groepen. Er werd geen associatie gevonden 
tussen de bestudeerde polymorfismen in de genen van het renine-angiotensine 
systeem. Het Asp-allel van het eNOS Glu298Asp polymorfisme was geassocieerd met 
atherosclerotische nierarteriestenose: met een odds ratio (95% betrouwbaarheids-
interval) van 1.44 (1.00-2.09) versus patiënten met hypertensie en middels angiografie 
bewezen gave arteriën, van 1.89 (1.24-2.87) versus patiënten met hypertensie in een 
huisartspraktijk en van 2.09 (1.29-3.38) versus patiënten zonder hypertensie in een 
huisartspraktijk. Echter, dit allel was eveneens significant vaker aanwezig bij patiënten 
met hypertensie en middels angiografie bewezen gave arteriën dan bij patiënten in de 
huisartspraktijk (zowel met als zonder hypertensie). Een kwart van de patiënten welke 
een nierangiografie ondergingen en geen nierarteriestenose bleken te hebben had 
elders in het lichaam uitingen van atherosclerose. Mogelijk is het Asp-allel of the eNOS 
Glu298Asp polymorfisme niet zo zeer specifiek geassocieerd met atherosclerotische 
nierarteriestenose als wel met atherosclerose sec.  
 
In het vijfde hoofdstuk bestudeerden we de nierdoorbloeding van beide nieren 
afzonderlijk bij patiënten in het angiografiecohort zonder afwijkingen van de nierarteriën. 
Bij 51% van deze patiënten vonden we duidelijke verschillen (asymmetrie) tussen de 
twee nieren. Patiënten met en zonder asymmetrie verschilden niet in leeftijd, body mass 
index, bloeddruk, geschatte creatinine klaring, niervolume of de mate van activiteit van 
het renine-angiotensine systeem. Mogelijk is er wel een relatie tussen asymmetrie en 
renale sympaticus activiteit, en dit is een aanwijzing dat deze verschillen deels of geheel 
functioneel zouden kunnen zijn. Patiënten met een asymmetrische nierdoorbloeding 
hadden vaker een vals-positieve uitkomst bij nierscintigrafie, een screeningstest welke 
op basis van onvoldoende diagnostische nauwkeurigheid weinig meer gebruikt wordt. 
Het frequente voorkomen van aanzienlijke verschillen in nierdoorbloeding tussen de 
twee nieren onderstreept het belang van het bestuderen van beide nieren afzonderlijk 
aangezien niet op voorhand aangenomen kan worden dat ze vanuit functioneel opzicht 
gelijk zijn.  
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In hoofdstuk 6 werd selectief de nierdoorbloeding gemeten bij patiënten met een 
unilaterale atherosclerotische nierarteriestenose, welke in ernst varieerde tussen de 15 
en 100%. Hieruit bleek dat de mate van stenosering een duidelijke relatie had met het 
voorkomen van asymmetrie in nierdoorbloeding tussen de twee nieren. Echter, 
patiënten met een ernstige nierarteriestenose hadden niet vaker asymmetrie in 
nierdoordoorbloeding dan patiënten zonder nierarteriestenose. Opmerkelijk was dat bij 
ongeveer de helft van de patiënten met een ernstige stenose er een betere 
doorbloeding was van de nier met de stenose dan de nier zonder de stenose. De 
overgrote meerderheid van patiënten met een ernstige stenose onderging 
revascularisatie. Hoewel bij patiënten met symmetrie en asymmetrie een gelijke daling 
van de gemiddelde bloeddruk gezien werd, daalde alleen bij patiënten met symmetrie 
ook de polsdruk.  
 
Hoofdstuk 7 beschrijft een meta-analyse van 29 studies (met in totaal 3701 patiënten) 
naar het effect van revascularisatie bij atherosclerotische nierarteriestenose op de 
nierfunctie op de middellange termijn. Hieruit concludeerden we dat het niet 
waarschijnlijk is dat revascularisatie zal leiden tot een belangrijke verbetering van de 
nierfunctie. 
 
De bovengenoemde studies worden in perspectief geplaatst in hoofdstuk 8. 
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Dankwoord 
Als u op deze pagina bent beland door alle voorgaande pagina’s te lezen zult u 
begrijpen dat ik ze onmogelijk allemaal heb kunnen schrijven zonder de hulp en 
inspiratie van anderen. Vele personen hebben bijgedragen aan de totstandkoming van 
dit proefschrift. Sommigen heel concreet. Anderen, niet minder essentieel, door 
regelmatig belangstelling te tonen voor het onderzoek, verhalen aan te horen, kopjes 
koffie in te schenken op momenten dat het even allemaal tegenzat, en met name in de 
laatste fase, vooral ook niet te vaak te vragen naar de vorderingen. Allen bedankt! Een 
aantal personen wil ik graag in het bijzonder noemen.   
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Prof. dr. Peter de Leeuw, ruim acht jaar geleden klopte ik bij je aan met de vraag of er 
misschien projecten waren waar ik mijn wetenschapstage op zinvolle wijze aan zou 
kunnen besteden. Met enthousiasme vertelde je me over de uiteenlopende projecten 
waar nog talloze onderzoeksvragen lagen te wachten. Dit enthousiasme bleek later 
kenmerkend voor je te zijn, en hiermee, in combinatie met je enorme kennis van de 
literatuur en (patho)fysiologie, wist je me voortdurend te motiveren nieuwe wegen in te 
slaan wanneer ik weer eens even vast zat. Ik bewaar goede herinneringen aan de 
schrijfweken in Vals, niet alleen vanuit wetenschappelijk oogpunt zeer effectief, maar 
ook een leuke manier om je eens van een andere, niet-wetenschappelijke kant te leren 
kennen. 
 
Dr. Boy Houben, jij hebt vanaf mijn start als frisse wetenschaps-co de dagelijkse 
begeleiding op je genomen. Nadat je me eerst de basis van enkele basisvaardigheden 
hebt moeten aanleren (“Kijk, dit is een computer en met deze knop gaat hij aan”) gingen 
we voortvarend aan de slag. De resultaten van deze stage hebben geleid tot hoofdstuk 
5 en een presentatie in de grote congreszaal in Milaan. Als bijwerking merkte ik hoe 
leuk ik het doen van onderzoek bleek te vinden en jouw enthousiaste wijze van 
begeleiding heeft daar een belangrijke rol in gespeeld. Als co-promotor bleef je nauw 
betrokken bij mijn onderzoeken en was je vaak degene die het gemakkelijkst te 
bereiken was voor overleg. Graag wil ik jou ook bedanken voor de gezelligheid tijdens 
de congressen en andere bijeenkomsten, al zal ik je padvindersinstinct node missen. 
 
Dr. Bram Kroon, nadat duidelijk werd dat de gestarte onderzoeken in mijn 
wetenschapsstage uitgebouwd zouden gaan worden tot een promotieonderzoek, kwam 
jij als co-promotor het “promotieteam” versterken. De clinicus in je zorgde dat de 
klinische relevantie van het onderzoek, waar nodig, bewaakt werd. Ik heb het 
gewaardeerd dat je me de ruimte en de vrijheid gaf mijn eigen plannen en ideeën te 
volgen.  
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inzet en het meedenken bij het uitvoeren van de diverse onderzoeken. 
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de titel heeft, is het duidelijk dat dit alleen tot stand kan komen door veel inspanningen 
op radiologisch vlak. Ik wil de afdeling radiologie van het azM, en in het bijzonder Prof 
dr. Jos van Engelshoven, drs. Derk Koster, dr. Kiam Oei, dr Boudewijn Vasbinder en dr. 
Michiel de Haan van harte bedanken voor de goede samenwerking. 
 
Drs. ir. Fons Kessels, dr. Patty Nelemans en dr. Karin Flobbe wil ik bedanken voor de 
vele constructieve methodologische en statistische discussies die we voerden 
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danken voor het kritisch beoordelen van  mijn manuscript. I wish to thank prof dr. P.F. 
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Tiny Wouters, ik wil je heel hartelijk bedanken voor je enorme inzet om mijn boekje er 
zo mooi uit te laten zien. Ik heb meermaals bewonderend staan kijken dat je in enkele 
minuten zoveel goeds kon doen voor een figuur waar ik dan al uren aan had gewerkt. 
Je weet precies wat er allemaal moet gebeuren voor je uiteindelijk voor de corona staat, 
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